CN101879140A - The nanoparticle and the sustained release compositions that comprise aryl-heterocyclic compounds - Google Patents
The nanoparticle and the sustained release compositions that comprise aryl-heterocyclic compounds Download PDFInfo
- Publication number
- CN101879140A CN101879140A CN2010102092071A CN201010209207A CN101879140A CN 101879140 A CN101879140 A CN 101879140A CN 2010102092071 A CN2010102092071 A CN 2010102092071A CN 201010209207 A CN201010209207 A CN 201010209207A CN 101879140 A CN101879140 A CN 101879140A
- Authority
- CN
- China
- Prior art keywords
- compositions
- less
- ziprasidone
- component
- granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 310
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 108
- 238000013268 sustained release Methods 0.000 title claims description 14
- 239000012730 sustained-release form Substances 0.000 title claims description 14
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims abstract description 254
- 229960000607 ziprasidone Drugs 0.000 claims abstract description 254
- 230000008859 change Effects 0.000 claims abstract description 98
- 239000008187 granular material Substances 0.000 claims abstract description 93
- 239000002552 dosage form Substances 0.000 claims abstract description 82
- 238000000034 method Methods 0.000 claims abstract description 58
- 239000003381 stabilizer Substances 0.000 claims abstract description 58
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 22
- 230000002902 bimodal effect Effects 0.000 claims abstract description 7
- -1 sorbitan ester Chemical class 0.000 claims description 83
- 239000003814 drug Substances 0.000 claims description 65
- 238000000576 coating method Methods 0.000 claims description 53
- 239000011248 coating agent Substances 0.000 claims description 52
- 229920000642 polymer Polymers 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 35
- 210000002381 plasma Anatomy 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 35
- 239000011159 matrix material Substances 0.000 claims description 34
- 239000002245 particle Substances 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 25
- 229920001223 polyethylene glycol Polymers 0.000 claims description 24
- 239000002202 Polyethylene glycol Substances 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 18
- 239000006185 dispersion Substances 0.000 claims description 16
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 15
- 229920001577 copolymer Polymers 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- 238000007599 discharging Methods 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 13
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 10
- 238000003860 storage Methods 0.000 claims description 10
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 9
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 8
- 235000010443 alginic acid Nutrition 0.000 claims description 8
- 229920000615 alginic acid Polymers 0.000 claims description 8
- 125000002091 cationic group Chemical group 0.000 claims description 8
- 230000003111 delayed effect Effects 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 8
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 7
- 235000010980 cellulose Nutrition 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 7
- 229940095374 tabloid Drugs 0.000 claims description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 235000010489 acacia gum Nutrition 0.000 claims description 6
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 6
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 229940014259 gelatin Drugs 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 5
- 229920000609 methyl cellulose Polymers 0.000 claims description 5
- 235000010981 methylcellulose Nutrition 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- 230000035699 permeability Effects 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- 239000012744 reinforcing agent Substances 0.000 claims description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 5
- AISMNBXOJRHCIA-UHFFFAOYSA-N trimethylazanium;bromide Chemical compound Br.CN(C)C AISMNBXOJRHCIA-UHFFFAOYSA-N 0.000 claims description 5
- 229920002907 Guar gum Polymers 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 229940072056 alginate Drugs 0.000 claims description 4
- 125000006177 alkyl benzyl group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- FXJNQQZSGLEFSR-UHFFFAOYSA-M benzyl-dimethyl-tetradecylazanium;chloride;hydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 FXJNQQZSGLEFSR-UHFFFAOYSA-M 0.000 claims description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 4
- 239000008116 calcium stearate Substances 0.000 claims description 4
- 235000013539 calcium stearate Nutrition 0.000 claims description 4
- 229940078456 calcium stearate Drugs 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 4
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- PLMFYJJFUUUCRZ-UHFFFAOYSA-M decyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)C PLMFYJJFUUUCRZ-UHFFFAOYSA-M 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 125000005131 dialkylammonium group Chemical group 0.000 claims description 4
- 239000007903 gelatin capsule Substances 0.000 claims description 4
- 235000010417 guar gum Nutrition 0.000 claims description 4
- 239000000665 guar gum Substances 0.000 claims description 4
- 229960002154 guar gum Drugs 0.000 claims description 4
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 230000000149 penetrating effect Effects 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 4
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 4
- YCYOWIYHCRGAAH-UHFFFAOYSA-M trimethyl(naphthalen-1-yl)azanium;chloride Chemical compound [Cl-].C1=CC=C2C([N+](C)(C)C)=CC=CC2=C1 YCYOWIYHCRGAAH-UHFFFAOYSA-M 0.000 claims description 4
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 3
- 102000016943 Muramidase Human genes 0.000 claims description 3
- 108010014251 Muramidase Proteins 0.000 claims description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 235000019270 ammonium chloride Nutrition 0.000 claims description 3
- JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 claims description 3
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 3
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 3
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 3
- 239000004325 lysozyme Substances 0.000 claims description 3
- 235000010335 lysozyme Nutrition 0.000 claims description 3
- 229960000274 lysozyme Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 3
- 229920005615 natural polymer Polymers 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229920001987 poloxamine Polymers 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 229920001059 synthetic polymer Polymers 0.000 claims description 3
- MOKBFXZQXUZAMV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOCCOCCOCCOCCO MOKBFXZQXUZAMV-UHFFFAOYSA-N 0.000 claims description 2
- UIRLNVFJXWEFHI-UHFFFAOYSA-N 2-chloroethyl(ethyl)azanium;bromide Chemical compound [Br-].CC[NH2+]CCCl UIRLNVFJXWEFHI-UHFFFAOYSA-N 0.000 claims description 2
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 claims description 2
- RUPBZQFQVRMKDG-UHFFFAOYSA-M Didecyldimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC RUPBZQFQVRMKDG-UHFFFAOYSA-M 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 229930182475 S-glycoside Natural products 0.000 claims description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 2
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 claims description 2
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 claims description 2
- WONCHGDEGMFLPR-UHFFFAOYSA-N [Cl-].[NH4+].CC(CCCCCCC)P(CCCCCCCC)CCCCCCCC Chemical compound [Cl-].[NH4+].CC(CCCCCCC)P(CCCCCCCC)CCCCCCCC WONCHGDEGMFLPR-UHFFFAOYSA-N 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- 150000005215 alkyl ethers Chemical class 0.000 claims description 2
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims description 2
- UUZYBYIOAZTMGC-UHFFFAOYSA-M benzyl(trimethyl)azanium;bromide Chemical compound [Br-].C[N+](C)(C)CC1=CC=CC=C1 UUZYBYIOAZTMGC-UHFFFAOYSA-M 0.000 claims description 2
- 229920001222 biopolymer Polymers 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 239000004359 castor oil Chemical class 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- CDJGWBCMWHSUHR-UHFFFAOYSA-M decyl(triethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCC[N+](CC)(CC)CC CDJGWBCMWHSUHR-UHFFFAOYSA-M 0.000 claims description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- GQOKIYDTHHZSCJ-UHFFFAOYSA-M dimethyl-bis(prop-2-enyl)azanium;chloride Chemical compound [Cl-].C=CC[N+](C)(C)CC=C GQOKIYDTHHZSCJ-UHFFFAOYSA-M 0.000 claims description 2
- JMGZBMRVDHKMKB-UHFFFAOYSA-L disodium;2-sulfobutanedioate Chemical compound [Na+].[Na+].OS(=O)(=O)C(C([O-])=O)CC([O-])=O JMGZBMRVDHKMKB-UHFFFAOYSA-L 0.000 claims description 2
- 229960000878 docusate sodium Drugs 0.000 claims description 2
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical group O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 claims description 2
- 230000001804 emulsifying effect Effects 0.000 claims description 2
- 239000008387 emulsifying waxe Substances 0.000 claims description 2
- 238000007046 ethoxylation reaction Methods 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Chemical class CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 229960002900 methylcellulose Drugs 0.000 claims description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920000570 polyether Polymers 0.000 claims description 2
- 229920005604 random copolymer Polymers 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 2
- 229960004274 stearic acid Drugs 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 2
- 125000005208 trialkylammonium group Chemical group 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 238000005260 corrosion Methods 0.000 claims 3
- 230000007797 corrosion Effects 0.000 claims 3
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 claims 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical group [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims 2
- NGXROVHZXLJEJG-UHFFFAOYSA-M ethyl-hydroxy-dimethylazanium;chloride Chemical compound [Cl-].CC[N+](C)(C)O NGXROVHZXLJEJG-UHFFFAOYSA-M 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims 1
- RMAJTXKOOKJAAV-UHFFFAOYSA-N 2,2-dihydroxyethyl(methyl)azanium;bromide Chemical compound [Br-].C[NH2+]CC(O)O RMAJTXKOOKJAAV-UHFFFAOYSA-N 0.000 claims 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- 241001044369 Amphion Species 0.000 claims 1
- NPFVFKZARBDQDF-UHFFFAOYSA-M [PH4+].[Br-].C(CCCCCCCCCCCCCCC)[N+](C)(C)C.[Br-] Chemical class [PH4+].[Br-].C(CCCCCCCCCCCCCCC)[N+](C)(C)C.[Br-] NPFVFKZARBDQDF-UHFFFAOYSA-M 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims 1
- 229920006317 cationic polymer Polymers 0.000 claims 1
- WERKISRAGZUECO-UHFFFAOYSA-M dodecyl-hydroxy-dimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)O WERKISRAGZUECO-UHFFFAOYSA-M 0.000 claims 1
- KHEHKKAUASTOLD-UHFFFAOYSA-M ethyl-dihydroxy-methylazanium;chloride Chemical compound [Cl-].CC[N+](C)(O)O KHEHKKAUASTOLD-UHFFFAOYSA-M 0.000 claims 1
- PNJRUPCMDXUIFY-UHFFFAOYSA-M ethyl-hydroxy-dimethylazanium;bromide Chemical compound [Br-].CC[N+](C)(C)O PNJRUPCMDXUIFY-UHFFFAOYSA-M 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims 1
- 210000001331 nose Anatomy 0.000 claims 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 claims 1
- 238000001238 wet grinding Methods 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 239000010408 film Substances 0.000 description 20
- 230000036470 plasma concentration Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 18
- 238000009792 diffusion process Methods 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 239000003826 tablet Substances 0.000 description 15
- 239000004094 surface-active agent Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- 235000021251 pulses Nutrition 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 230000003204 osmotic effect Effects 0.000 description 11
- 238000001764 infiltration Methods 0.000 description 10
- 230000008595 infiltration Effects 0.000 description 10
- 230000002085 persistent effect Effects 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 230000003213 activating effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229960001375 lactose Drugs 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000003578 releasing effect Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229940083542 sodium Drugs 0.000 description 6
- 235000015424 sodium Nutrition 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 235000010419 agar Nutrition 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003093 cationic surfactant Substances 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 239000004014 plasticizer Substances 0.000 description 5
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 241001597008 Nomeidae Species 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 238000005660 chlorination reaction Methods 0.000 description 4
- 239000003405 delayed action preparation Substances 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- 239000008151 electrolyte solution Substances 0.000 description 4
- 229940021013 electrolyte solution Drugs 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 230000002706 hydrostatic effect Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000006186 oral dosage form Substances 0.000 description 4
- 230000002688 persistence Effects 0.000 description 4
- 229960003742 phenol Drugs 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
- UZIQYAYUUNMDMU-UHFFFAOYSA-N N.[Br+] Chemical compound N.[Br+] UZIQYAYUUNMDMU-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 150000003868 ammonium compounds Chemical class 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 229920002689 polyvinyl acetate Polymers 0.000 description 3
- 239000011118 polyvinyl acetate Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- WLQZEFFFIUHSJB-UHFFFAOYSA-N ziprasidone mesylate trihydrate Chemical compound O.O.O.CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 WLQZEFFFIUHSJB-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- JNOZGFXJZQXOSU-UHFFFAOYSA-N 1-chloro-2-methylpropan-2-ol Chemical compound CC(C)(O)CCl JNOZGFXJZQXOSU-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 2
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 2
- SIXWIUJQBBANGK-UHFFFAOYSA-N 4-(4-fluorophenyl)-1h-pyrazol-5-amine Chemical compound N1N=CC(C=2C=CC(F)=CC=2)=C1N SIXWIUJQBBANGK-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- DMIMWGHYIPFAIF-UHFFFAOYSA-N 5-nitro-2-piperidin-1-ylaniline Chemical compound NC1=CC([N+]([O-])=O)=CC=C1N1CCCCC1 DMIMWGHYIPFAIF-UHFFFAOYSA-N 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KCXZNSGUUQJJTR-UHFFFAOYSA-N Di-n-hexyl phthalate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCC KCXZNSGUUQJJTR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019133 Hangover Diseases 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- MURWRBWZIMXKGC-UHFFFAOYSA-N Phthalsaeure-butylester-octylester Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC MURWRBWZIMXKGC-UHFFFAOYSA-N 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000015125 Sterculia urens Nutrition 0.000 description 2
- 240000001058 Sterculia urens Species 0.000 description 2
- 230000002730 additional effect Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- WZEMSIKSCALWJZ-UHFFFAOYSA-N azane;ethanol Chemical compound N.CCO.CCO WZEMSIKSCALWJZ-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229950010118 cellacefate Drugs 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- IHDIFQKZWSOIBB-UHFFFAOYSA-M dodecyl-[(4-ethylphenyl)methyl]-dimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=C(CC)C=C1 IHDIFQKZWSOIBB-UHFFFAOYSA-M 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- YDLYQMBWCWFRAI-UHFFFAOYSA-N hexatriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC YDLYQMBWCWFRAI-UHFFFAOYSA-N 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229960004487 ziprasidone mesylate Drugs 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- HMDFOXQIYPYCRX-UHFFFAOYSA-N 1-(2-chloropropan-2-yl)-2-dodecylbenzene Chemical compound CCCCCCCCCCCCC1=CC=CC=C1C(C)(C)Cl HMDFOXQIYPYCRX-UHFFFAOYSA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical group CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- AFLDFEASYWNJGX-UHFFFAOYSA-N 1-(4-iodophenyl)-n-propan-2-ylpropan-2-amine;hydrochloride Chemical compound Cl.CC(C)NC(C)CC1=CC=C(I)C=C1 AFLDFEASYWNJGX-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical compound CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- CTTJWXVQRJUJQW-UHFFFAOYSA-N 2,2-dioctyl-3-sulfobutanedioic acid Chemical compound CCCCCCCCC(C(O)=O)(C(C(O)=O)S(O)(=O)=O)CCCCCCCC CTTJWXVQRJUJQW-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JFIILZYEGAFUOP-UHFFFAOYSA-N 2-hexyldecanedioic acid Chemical compound CCCCCCC(C(O)=O)CCCCCCCC(O)=O JFIILZYEGAFUOP-UHFFFAOYSA-N 0.000 description 1
- CQLCSKMKNLINGZ-UHFFFAOYSA-N 2-hexylhexanedioic acid Chemical compound CCCCCCC(C(O)=O)CCCC(O)=O CQLCSKMKNLINGZ-UHFFFAOYSA-N 0.000 description 1
- YVCZEUXTTLOCQA-UHFFFAOYSA-N 2-hexylnonanedioic acid Chemical compound CCCCCCC(C(O)=O)CCCCCCC(O)=O YVCZEUXTTLOCQA-UHFFFAOYSA-N 0.000 description 1
- FVEWVVDBRQZLSJ-QTWKXRMISA-N 2-hydroxyethyl-dimethyl-[3-[[(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoyl]amino]propyl]azanium;chloride Chemical compound [Cl-].OCC[N+](C)(C)CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FVEWVVDBRQZLSJ-QTWKXRMISA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- SKMXQYHBQDZWPS-UHFFFAOYSA-N 3-chloro-2-methyltridecan-2-ol Chemical compound ClC(C(O)(C)C)CCCCCCCCCC SKMXQYHBQDZWPS-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-M 4-methoxybenzoate Chemical compound COC1=CC=C(C([O-])=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- GOJCZVPJCKEBQV-UHFFFAOYSA-N Butyl phthalyl butylglycolate Chemical compound CCCCOC(=O)COC(=O)C1=CC=CC=C1C(=O)OCCCC GOJCZVPJCKEBQV-UHFFFAOYSA-N 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- FTVDCUVKXCVQOT-UHFFFAOYSA-N CCCl(C)(O)O Chemical compound CCCl(C)(O)O FTVDCUVKXCVQOT-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical class COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 1
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- QWVMSYBGKWZIIE-RDFNRINOSA-N Flavochrome Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CCCC(C)(C)C2=C1)C=CC=C(/C)C=CC3C(=CCCC3(C)C)C QWVMSYBGKWZIIE-RDFNRINOSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 229920003115 HPC-SL Polymers 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- IEBJZLRZRKTGFN-UHFFFAOYSA-N N=NC=NN.N=NC=NN.C1=CC=CC=C1 Chemical compound N=NC=NN.N=NC=NN.C1=CC=CC=C1 IEBJZLRZRKTGFN-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 238000001016 Ostwald ripening Methods 0.000 description 1
- 229940049937 Pgp inhibitor Drugs 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NJSSICCENMLTKO-HRCBOCMUSA-N [(1r,2s,4r,5r)-3-hydroxy-4-(4-methylphenyl)sulfonyloxy-6,8-dioxabicyclo[3.2.1]octan-2-yl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)O[C@H]1C(O)[C@@H](OS(=O)(=O)C=2C=CC(C)=CC=2)[C@@H]2OC[C@H]1O2 NJSSICCENMLTKO-HRCBOCMUSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- IBNQLYMPUGQNLN-UHFFFAOYSA-M benzyl-[2-(4-dodecanoylphenoxy)ethyl]-dimethylazanium;chloride Chemical compound [Cl-].C1=CC(C(=O)CCCCCCCCCCC)=CC=C1OCC[N+](C)(C)CC1=CC=CC=C1 IBNQLYMPUGQNLN-UHFFFAOYSA-M 0.000 description 1
- OCBHHZMJRVXXQK-UHFFFAOYSA-M benzyl-dimethyl-tetradecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 OCBHHZMJRVXXQK-UHFFFAOYSA-M 0.000 description 1
- BWNMWDJZWBEKKJ-UHFFFAOYSA-M benzyl-docosyl-dimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 BWNMWDJZWBEKKJ-UHFFFAOYSA-M 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000008372 bubblegum flavor Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- OCHFNTLZOZPXFE-JEDNCBNOSA-N carbonic acid;(2s)-2,6-diaminohexanoic acid Chemical compound OC(O)=O.NCCCC[C@H](N)C(O)=O OCHFNTLZOZPXFE-JEDNCBNOSA-N 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229920001727 cellulose butyrate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- QDYLMAYUEZBUFO-UHFFFAOYSA-N cetalkonium chloride Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 QDYLMAYUEZBUFO-UHFFFAOYSA-N 0.000 description 1
- 229960000228 cetalkonium chloride Drugs 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 229960000800 cetrimonium bromide Drugs 0.000 description 1
- 229960002788 cetrimonium chloride Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000110 cooling liquid Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 229920003020 cross-linked polyethylene Polymers 0.000 description 1
- 239000004703 cross-linked polyethylene Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- VWTINHYPRWEBQY-UHFFFAOYSA-N denatonium Chemical compound [O-]C(=O)C1=CC=CC=C1.C=1C=CC=CC=1C[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C VWTINHYPRWEBQY-UHFFFAOYSA-N 0.000 description 1
- 229960001610 denatonium benzoate Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- UCVPKAZCQPRWAY-UHFFFAOYSA-N dibenzyl benzene-1,2-dicarboxylate Chemical compound C=1C=CC=C(C(=O)OCC=2C=CC=CC=2)C=1C(=O)OCC1=CC=CC=C1 UCVPKAZCQPRWAY-UHFFFAOYSA-N 0.000 description 1
- PCYQQSKDZQTOQG-NXEZZACHSA-N dibutyl (2r,3r)-2,3-dihydroxybutanedioate Chemical compound CCCCOC(=O)[C@H](O)[C@@H](O)C(=O)OCCCC PCYQQSKDZQTOQG-NXEZZACHSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- HBGGXOJOCNVPFY-UHFFFAOYSA-N diisononyl phthalate Chemical compound CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C HBGGXOJOCNVPFY-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- XWVQUJDBOICHGH-UHFFFAOYSA-N dioctyl nonanedioate Chemical compound CCCCCCCCOC(=O)CCCCCCCC(=O)OCCCCCCCC XWVQUJDBOICHGH-UHFFFAOYSA-N 0.000 description 1
- RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- QWVMSYBGKWZIIE-FZKBJVJCSA-N flavochrome Chemical compound O1C2(C)CCCC(C)(C)C2=CC1C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1C(C)=CCCC1(C)C QWVMSYBGKWZIIE-FZKBJVJCSA-N 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000002748 glycoprotein P inhibitor Substances 0.000 description 1
- 239000008202 granule composition Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- MHUQWGIAOKFBJB-UHFFFAOYSA-N heptatriacontan-19-yl(dimethyl)azanium chloride Chemical compound [Cl-].C(CCCCCCCCCCCCCCCCC)C([NH+](C)C)CCCCCCCCCCCCCCCCCC MHUQWGIAOKFBJB-UHFFFAOYSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229950007325 lauralkonium chloride Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- VHRYZQNGTZXDNX-UHFFFAOYSA-N methacryloyl chloride Chemical compound CC(=C)C(Cl)=O VHRYZQNGTZXDNX-UHFFFAOYSA-N 0.000 description 1
- 229960002285 methylbenzethonium chloride Drugs 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- UPHWVVKYDQHTCF-UHFFFAOYSA-N octadecylazanium;acetate Chemical compound CC(O)=O.CCCCCCCCCCCCCCCCCCN UPHWVVKYDQHTCF-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N ortho-methoxybenzoic acid Natural products COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- 150000002927 oxygen compounds Chemical class 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229940089970 quaternium-14 Drugs 0.000 description 1
- 229940101631 quaternium-18 hectorite Drugs 0.000 description 1
- 229940097319 quaternium-22 Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003784 tall oil Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- IIYFAKIEWZDVMP-UHFFFAOYSA-N tridecane Chemical class CCCCCCCCCCCCC IIYFAKIEWZDVMP-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- FZGRPBJBMUNMQH-UHFFFAOYSA-N trimethyl-$l^{3}-chlorane Chemical compound CCl(C)C FZGRPBJBMUNMQH-UHFFFAOYSA-N 0.000 description 1
- WDRCVXGINNJWPH-UHFFFAOYSA-N tris(6-methylheptyl) benzene-1,2,4-tricarboxylate Chemical compound CC(C)CCCCCOC(=O)C1=CC=C(C(=O)OCCCCCC(C)C)C(C(=O)OCCCCCC(C)C)=C1 WDRCVXGINNJWPH-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a kind of compositions that comprises Ziprasidone, be used for the treatment of and prevent schizophrenia and similar psychiatric disturbance.In one embodiment, said composition comprises the nanoparticle granule that contains Ziprasidone and at least a surface stabilizer.Effective mean diameter of this nanoparticle is less than about 2000nm.In another embodiment, said composition comprises the change release composition, and after being applied to the patient, it sends Ziprasidone with bimodal, multimodal or continuation mode.The present invention also provides the dosage form that comprises said composition, and is used for the treatment of and prevents the method for schizophrenia and similar psychiatric disturbance.
Description
The application is dividing an application of 2006800302325 patent application for application number.
Invention field
The present invention relates to be used to prevent and treat the compositions of schizophrenia and similar psychiatric disturbance.Especially, the present invention relates to comprise aryl-heterocyclic drug chemical compound, for example the compositions of Ziprasidone.In one aspect of the invention, said composition is the form of nanoparticle, and also comprises at least a surface stabilizer.In yet another aspect, the present invention also relates to control and send aryl-heterocyclic drug chemical compound, for example novel form of Ziprasidone and prevention and treatment schizophrenia and the similarly method of psychiatric disturbance.
Background of invention
Ziprasidone, chemistry 5-[2-[4-(1 by name, 2-benzisothiazole-3-yl)-and the 1-piperazinyl] ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one, it is a kind of benzothiazole based piperazine derivative, be used for the treatment of psychiatric disorders for example schizophrenia, hallucination, vain hope, hostility and other bipolar disorders as major tranquilizer, and can not improve lipid and other blood fat.The empirical formula of Ziprasidone is C
21H
21ClN
4OS, molecular weight are 412.94 (free alkalis).
The chemical constitution of Ziprasidone is as follows:
Ziprasidone can be used as the registrar name of an article of Pfizer Inc. in the U.S.
The part of the dosage form that provides is used.With
The Ziprasidone that capsule exists is the hydrochloride form of Ziprasidone, i.e. 5-(2-(4-(1,2-benzisothiazole-3-yl) piperazinyl) ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one list hydrochloric acid monohydrate.This salt is that white arrives the baby pink powder, and fusing point is 300 ℃, and empirical formula is C
21H
21ClN
4OS-HCl-H
2O, molecular weight are 467.42.
Capsule is the capsule oral that is used for 20mg, 40mg, 60mg and 80mg.
Non-active ingredient in the capsule comprises lactose, pregelatinized starch and magnesium stearate.Patient's common dose comprises that adult's dosage for the treatment of schizoid peroral dosage form (capsule) is 20 milligrams (mg), every day twice, uses with food.Higher dosage comprises the dosage of 80mg, twice of every day.
Ziprasidone can be used for intramuscular injection, and with the form of ziprasidone mesylate, commodity are called injection
Injection
The ziprasidone mesylate trihydrate that comprises lyophilized form, 5-(2-(4-(1,2-benzisothiazole-3-yl) piperazinyl) ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one, mesylate, trihydrate (empirical formula: C
21H
21ClN
4OS-CH
3SO
3H-3H
2O; Molecular weight: 563.09).Injection
Can in single dose vial, be the ziprasidone mesylate that comprises 20mg Ziprasidone/mL.U.S. food and Drug Administration (FDA) have ratified Ziprasidone can treat schizophrenia, and the Ziprasidone of having ratified the intramuscular injection form can be used for schizophrenic's acute psychokinesia.
The elimination half-life of Ziprasidone is about 7 hours.In 1 to 3 day, reach Cpss.The bioavailability of Ziprasidone is about 60% when taking with food.Reported, increased to gradually
The about twentieth patient of high dose (360mg every day) has shown cognitive remarkable improvement.
The Ziprasidone chemical compound has been described: U.S. patent 4,831,031 in following document; 6,110,918; 6,245,765; 6,150,366; 6,232,304; 6,399,777; With 6,245,766.U.S. Patent Publication 2004/0138237 and 2004/0146562 discloses the Injectable depot formulations of Ziprasidone, wherein uses the active Ziprasidone chemical compound of cyclodextrin solubilising to form suspending agent.
The patient that Ziprasidone is suffered from schizophrenia and similar mental disorder for therapeutic treatment has higher effect.But if satisfy the needs of taking 2 Ziprasidones every day and the further needs of one after each meal Ziprasidone, strict patient's compliance is a key factor of Ziprasidone treatment schizophrenia and similar mental disorder.In addition, so frequent use the concern that needs the hygiene care personnel usually, and therefore caused the cost relevant very high with the Ziprasidone treatment.Therefore, this area needs new Ziprasidone compositions, and it has overcome these problem and other problems relevant with its use when treating schizophrenia with similar psychosis.
In addition, Ziprasidone is water-soluble hardly.This relatively poor water solublity has caused relatively poor bioavailability.
The invention summary
One embodiment of the invention comprise a kind of nanoparticle compositions, comprise: (A) Ziprasidone; (B) at least a surface stabilizer.This surface stabilizer can adsorb or be attached on the particulate surface of nanoparticle.The particulate effective mean diameter of this nanoparticle is less than about 2,000nm.This nanoparticle compositions can be chosen wantonly and comprise additional activity composition and/or the acceptable excipient of one or more pharmacy that one or more are used to prevent and treat schizophrenia and similar psychiatric disturbance.In these embodiments, the patient that this nanoparticle compositions is applied under feed or the fasting state will be bioequivalent, can show similar pharmacokinetics.
The present invention also relates to change release composition, wherein first component of said composition comprises the granule that comprises active component and at least a particulate second component that comprises active component that comprises second portion of first, wherein every kind of component has different rates of release and/or persistent period and wherein at least a described component and comprises Ziprasidone.The granule of described second component at least is change to discharge (MR) form, and for example, bag is changed and discharges coating or comprise or mixed change release matrix material.After the patient was oral, said composition discharged one or more active component with bimodal or multimodal mode.This change release composition can comprise the Ziprasidone and at least a surface stabilizer of nanoparticle form, can choose wantonly to comprise additional activity composition and/or the acceptable excipient of one or more pharmacy that one or more are used to prevent and treat schizophrenia and similar psychiatric disturbance.
First component of this change release composition can show different release profiles, comprise that the nearly all active component that wherein comprises in first component discharges immediately behind form of administration, after postponing a period of time, discharge (postponing to discharge) immediately, or the curve that slowly discharges in a period of time.In one embodiment, the active component that comprises in this dosage form first component after being applied to the patient discharges rapidly.The release profiles that " discharging rapidly " used herein comprises, wherein the active component at least about 80% of the component of this dosage form is being used back release in about 1 hour, term " postpones to discharge " release profiles that comprises, wherein the active component of the component of this dosage form discharges (quick or slow) after postponing a period of time, the release profiles that term " sustained release " and " prolong discharge " comprise slowly discharges comprising the active component at least about 80% in the component of this dosage form.
Second component of this change release composition also shows a lot of release profiles, comprises release profiles immediately, postpones release profiles or sustained release curve.In one embodiment, this second component display delay release profiles, wherein the active component of this component discharges after postponing a period of time.In another embodiment, this second component shows sustained release curve, and wherein the active component of this component discharges in about 24 hours time using back about 12.
Component shows that the release profiles of this active component from said composition is bimodal in the bi-component embodiment of different release profiles therein.First component shows release profiles immediately therein, and in the embodiment of the second component display delay release profiles, being discharged into active component at active component from first component has a time delay between discharging from second component.Amount by change discharging coating and/or composition or by changing the release matrix amount of substance and/or forming in order to reach the persistence length that required release profiles changes time delay.Therefore, the persistence length of time delay can be designed for the required curve of blood plasma of simulation.
First component shows release profiles immediately therein, and second component shows that the active component in first and second components discharges in the embodiment of sustained release curve in the different time.In such embodiments, immediate-release component is used for by making from being administered to the treatment time minimum of effective plasma concentration level facilitation, and one or more subsequent component are used to make the variation of plasma concentration level minimum and/or keep the effective plasma concentration of treatment during dosing interval.In such embodiment, the active component rapid release in first component, the active component in second component discharge using in about 12 hours time of back.In another such embodiment, the active component rapid release in first component, the active component in second component discharge using in about 24 hours time of back.In another such embodiment, the active component rapid release in first component, the active component in second component are gone through about 12 hours time release after using.In another such embodiment, the active component rapid release in first component, the active component in second component are gone through about 24 hours time release after using.In another such embodiment, the time that the active component rapid release in first component, the active component in second component were gone through after using at least about 12 hours discharges.In another such embodiment, the time that the active component rapid release in first component, the active component in second component were gone through after using at least about 24 hours discharges.
Dosage form of the present invention comprises immediate-release component and at least a change discharges component, the curve of blood plasma of using this dosage form and producing is substantially similar to twice of continuous administration or the curve of blood plasma that produces of I R dosage form repeatedly, or uses the curve of blood plasma that IR and MR dosage form produce respectively.Change release composition of the present invention is useful especially for using the Ziprasidone of using 2 common every day.In one embodiment of the invention, said composition is sent Ziprasidone in bimodal mode.After using, said composition has produced a kind of curve of blood plasma, and its IR dosage of simulating basically according to typical twice Ziprasidone of therapeutic scheme continuous administration acquires curve of blood plasma.
According to another aspect of the present invention, said composition can be designed for the generation curve of blood plasma, and it makes and twice of continuous administration or the repeatedly relevant relevant minimum or disappearance of change of plasma concentration level of IR dosage form.In these embodiments, said composition can provide immediate-release component with by making from being administered to the time of treatment between the effective plasma concentration level the shortest and facilitation, and provides at least a change to discharge component to keep the effective plasma concentration level of treatment in whole dosing interval.Ziprasidone can be included in the nanoparticle granule that also comprises at least a surface stabilizer.
At people's such as Devane United States Patent (USP) 6,228,398 and 6,730, open and claimedly similarly change release composition in 325 with this paper.
The present invention also relates to dosage form by preparation of compositions of the present invention.In one embodiment, this dosage form is the solid oral dosage form that comprises change release composition of the present invention.This peroral dosage form can utilize, for example erodable preparation, DIFFUSION CONTROLLED preparation and infiltration control preparation.In such embodiments, the accumulated dose that is included in this dosage form discharges with pulse or continuation mode.In such embodiment, the part of accumulated dose discharges immediately, and beginning effect rapidly, the remainder of accumulated dose is after time delay or go through up to about 24 hours time and discharge.
In another embodiment, this dosage form is the injectable depot formulations that comprises the nanoparticle compositions, and wherein this nanoparticle compositions comprises Ziprasidone.This depot formulations is lentamente with medicine dissolution and be discharged in patient's the circulation.The single injection of said preparation can provide the Ziprasidone of the effective plasma concentration of treatment that reaches 3 months
The present invention also relates to the nanoparticle method for compositions that a kind of preparation comprises Ziprasidone.This method is included under the condition that is enough to provide the stable nanoparticle compositions that comprises Ziprasidone, and the nanoparticle granule that will comprise Ziprasidone contacts the step of a period of time with at least a surface stabilizer.
The invention further relates to the method that includes but not limited to prevent and treat schizophrenia and similar mental disorder for the treatment of.This method comprises the compositions to patient's administering therapeutic effective dose, for example comprises the step of the nanoparticle compositions of Ziprasidone.
Compositions of the present invention and dosage form are used to reduce required administration frequency, therefore strengthen patient's convenience and improved patient's compliance, therefore, having improved all needs the Ziprasidone treatment, includes but not limited to prevent and treat the therapeutic outcome of schizophrenia and similar psychiatric disturbance.This approach can substitute the Ziprasidone dosage form of repeatedly using conventional every day.
Above-mentioned generality is described and following detailed description is an illustrative and indicative, is to attempt to provide further explanation for the present invention for required protection.According to following detailed description of the present invention, other purpose, advantage and new feature will be conspicuous for those skilled in the art.
Detailed Description Of The Invention
Use several in this article as hereinafter describe the present invention with listed definition in full.
" pact " used herein one of ordinary skill in the art will appreciate that, have difference to a certain degree in the context of its use.If it is unclear providing for those of ordinary skills in its employed context, " pact " just is meant that being this particular term to the maximum adds deduct 10% so.
" Ziprasidone " used herein comprises Ziprasidone, the acceptable salt of its pharmacy, acid, ester, metabolite, complex or other derivants and they every kind of stereoisomer separately comprises the mixture, racemate of two or more stereoisomers or other.
The amount that the pharmacology that phrase used herein " Ziprasidone of treatment effective dose " is meant provides specific replys, Ziprasidone is applied to the patient who much needs associated treatment for this reason.What should emphasize is, always the particular patient that the Ziprasidone of treatment effective dose is applied to particular case under is not necessarily effective for treatment disease as herein described, although those skilled in the art think that this dosage is to treat effective dose.
Term used herein " granule " is meant a kind of state of material, it is characterized in that being discrete particle, piller, pearl or granule, no matter and its size, shape or form.
Term used herein " many granules " is meant a plurality of granule, piller, pearl, granule or its mixture that disperse or reunite, no matter and its size, shape or form.As herein describedly comprise granose compositions and be also referred to as " many particulate compositions ".
Term " nanoparticle " is meant a kind of many granules, and wherein this particulate effective mean diameter is that diameter is less than about 2000nm (2 microns).The compositions that comprises nanoparticle as herein described is also referred to as " nanoparticle compositions ".
Term used herein " effectively mean diameter " in order to describe many granules (for example, nanoparticle), is meant that its granule of at least 50% is specific size.Therefore, " effectively mean diameter be that diameter is less than about 2000nm " is meant that wherein at least 50% particulate diameter is less than about 2000nm." D50 " is meant in many granules that 50% granule is at this particle diameter below particle diameter.Similarly, " D90 " is meant in many granules that 90% granule is at this particle diameter below particle diameter.
As for stable particle in this article, " stablizing " is meant but is not limited to, one or more following parameters: (1) granule not can owing to captivation between granule or along with the time particle diameter increase significantly and slightly the flocculation or in bulk; (2) particulate physical arrangement can for example not change the crystal phase into by amorphous phase along with the time changes; (3) this granule is chemically stable; And/or (4) active component in the preparation of nanoparticle of the present invention does not carry out heating steps on particulate fusing point or fusing point.
" being insoluble in the medicine of water " used herein is meant dissolubility in water less than about 30mg/ml, less than about 20mg/ml, and less than about 10mg/ml, or less than the medicine of about 1mg/ml.
Term used herein " changes release " and comprises non-release immediately, and comprises that sustained release, prolongation discharge, continue release and delay release.
Term used herein " time delay " is meant is using the dosage form that comprises compositions of the present invention and the described active component time between discharging from specific components.
Term used herein " lag time " is meant and discharges the component from active component from compositions and the time of described active component between discharging from another component of compositions.
Term used herein " erodable " is meant can be by intravital material effect wearing and tearing, minimizing or rotten preparation.
Term used herein " DIFFUSION CONTROLLED " is meant as autonomic movement for example from the preparation of high concentration to result's diffusion of low concentration region motion.
Term used herein " infiltration control " is meant that wherein this infiltration can make the concentration balance of film both sides preparation as the preparation of result's diffusion of the solution motion that enters higher concentration by semipermeable membrane.
I. the nanoparticle compositions that comprises Ziprasidone
The invention provides a kind of particulate nanoparticle compositions that comprises, wherein this granule comprises: (A) Ziprasidone or its salt or derivant; (B) at least a surface stabilizer.In U.S. patent 5,145,684, describe the nanoparticle compositions first, in following document, also described the compositions of nanoparticle activating agent, for example, U.S. patent 5,298,262; 5,302,401; 5,318,767; 5,326,552; 5,328,404; 5,336,507; 5,340,564; 5,346,702; 5,349,957; 5,352,459; 5,399,363; 5,494,683; 5,401,492; 5,429,824; 5,447,710; 5,451,393; 5,466,440; 5,470,583; 5,472,683; 5,500,204; 5,518,738; 5,521,218; 5,525,328; 5,543,133; 5,552,160; 5,565,188; 5,569,448; 5,571,536; 5,573,749; 5,573,750; 5,573,783; 5,580,579; 5,585,108; 5,587,143; 5,591,456; 5,593,657; 5,622,938; 5,628,981; 5,643,552; 5,718,388; 5,718,919; 5,747,001; 5,834,025; 6,045,829; 6,068,858; 6,153,225; 6,165,506; 6,221,400; 6,264,922; 6,267,989; 6,270,806; 6,316,029; 6,375,986; 6,428,814; 6,431,478; 6,432,381; 6,582,285; 6,592,903; 6,656,504; 6,742,734; 6,745,962; 6,811,767; 6,908,626; 6,969,529; 6,976,647; With 6,991,191; With U.S. patent disclosure 20020012675; 20050276974; 20050238725; 20050233001; 20050147664; 20050063913; 20050042177; 20050031691; 20050019412; 20050004049; 20040258758; 20040258757; 20040229038; 20040208833; 20040195413; 20040156895; 20040156872; 20040141925; 20040115134; 20040105889; 20040105778; 20040101566; 20040057905; 20040033267; 20040033202; 20040018242; 20040015134; 20030232796; 20030215502; 20030185869; 20030181411; 20030137067; 20030108616; 20030095928; 20030087308; 20030023203; 20020179758; 20020012675; With 20010053664.Described unbodied granule compositions in the lower class document, for example the U.S. patent 4,783, and 484; 4,826,689; 4,997,454; 5,741,522; 5,776,496.
As mentioned above, particulate effective mean diameter is that diameter is less than about 2000nm (that is, 2 microns) in the nanoparticle compositions of the present invention.In embodiments of the invention, when passing through light scattering method, when microscopy or other suitable methods were measured, effectively mean diameter can be that diameter is for example less than about 1900nm, less than about 1800nm, less than about 1700nm, less than about 1600nm, less than about 1500nm, less than about 1400nm, less than about 1300nm, less than about 1200nm, less than about 1100nm, less than about 1000nm, less than about 900nm, less than about 800nm, less than about 700nm, less than about 600nm, less than about 500nm, less than about 400nm, less than about 300nm, less than about 250nm, less than about 200nm, less than about 150nm, less than about 100nm, less than about 75nm or less than about 50nm.
This nanoparticle granule can be crystal phase, amorphous phase, hemihedral crystal bulk phase, half amorphous phase or its mixture.
Except solid dosage forms is less, compare with the nanoparticle compositions existing routine that comprises Ziprasidone, non-, nanoparticle compositions display of the present invention the bioavailability that increases and the Ziprasidone that needs smaller dose.In one embodiment of the invention, the bioavailability of nanoparticle compositions of the present invention is than the Ziprasidone of using in regular dosage form high about 50%.In other embodiments, the bioavailability of nanoparticle compositions of the present invention ratio Ziprasidone in regular dosage form high about 40%, high about 30%, high about 20% or height about 10%.
When measuring after using predose to mammalian subject, this nanoparticle compositions also can have the pharmacokinetic curve of expectation.The pharmacokinetic curve of the expectation of said composition includes but not limited to: (1) when using the blood plasma of post analysis mammalian subject, the C of preferred Ziprasidone
MaxC greater than the non-nanoparticle compositions of the identical Ziprasidone of using same dose
MaxAnd/or (2) when using the blood plasma of post analysis mammalian subject, and the AUC of preferred Ziprasidone is greater than the AUC of the non-nanoparticle compositions of the identical Ziprasidone of using same dose; And/or (3) when using the blood plasma of post analysis mammalian subject, the T of preferred Ziprasidone
MaxT less than the non-nanoparticle compositions of the identical Ziprasidone of using same dose
Max
In one embodiment of the invention, with respect to the T of the non-nanoparticle compositions of the identical Ziprasidone of same dose
Max, nanoparticle compositions display of the present invention goes out, for example the T of its Ziprasidone that comprises
MaxBe no more than its about 90%.In other embodiments of the present invention, with respect to the T of the non-nanoparticle compositions of the identical Ziprasidone of same dose
Max, nanoparticle compositions display of the present invention goes out, for example the T of its Ziprasidone that comprises
MaxBe no more than the about 80% of its, be no more than the about 70% of its, be no more than the about 60% of its, be no more than its about 50%, be no more than the about 30% of its, be no more than the about 25% of its, be no more than its about 20%, be no more than the about 15% of its, be no more than the about 10% of its, or be no more than its about 5%.In one embodiment of the invention, the T of Ziprasidone when analyzing the blood plasma of mammalian subject
MaxBe to use the back less than about 6 to about 8 hours.In other embodiments of the present invention, the T of Ziprasidone
MaxBe to use the back less than about 6 hours, less than about 5 hours, less than about 4 hours, less than about 3 hours, less than about 2 hours, less than about 1 hour or less than about 30 minutes.
In one embodiment of the invention, with respect to the C of the non-nanoparticle compositions of the identical Ziprasidone of same dose
Max, nanoparticle compositions display of the present invention goes out, for example the C of its Ziprasidone that comprises
MaxBe at least its about 50%.In other embodiments of the present invention, with respect to the C of the non-nanoparticle compositions of the identical Ziprasidone of same dose
Max, nanoparticle compositions display of the present invention goes out, for example the C of its Ziprasidone that comprises
MaxBigger than it at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, at least about 600%, at least about 700%, at least about 800%, at least about 900%, at least about 1000%, at least about 1100%, at least about 1200%, at least about 1300%, at least about 1400%, at least about 1500%, at least about 1600%, at least about 1700%, at least about 1800%, at least about 1900%.
In one embodiment of the invention, with respect to the AUC of the non-nanoparticle compositions of the identical Ziprasidone of same dose, nanoparticle compositions display of the present invention goes out, and for example the AUC of its Ziprasidone that comprises is bigger at least about 25% than it.In other embodiments of the present invention, with respect to the AUC of the non-nanoparticle compositions of the identical Ziprasidone of same dose, nanoparticle compositions display of the present invention goes out, for example the AUC of its Ziprasidone that comprises is bigger at least about 50% than it, at least about 75%, at least about 100%, at least about 125%, at least about 150%, at least about 175%, at least about 200%, at least about 225%, at least about 250%, at least about 275%, at least about 300%, at least about 350%, at least about 400%, at least about 450%, at least about 500%, at least about 550%, at least about 600%, at least about 650%, at least about 700%, at least about 750%, at least about 800%, at least about 850%, at least about 900%, at least about 950%, at least about 1000%, at least about 1050%, at least about 1100%, at least about 1150%, or at least about 1200%.
The present invention includes a kind of nanoparticle compositions, wherein, do not absorbed patient's the feed of said composition or the influence of fasting state substantially at the pharmacokinetic curve of using the back Ziprasidone.This means, when on the feed with fasting state under when using this nanoparticle compositions, the speed that amount that Ziprasidone absorbs or Ziprasidone absorb does not have difference basically.Ziprasidone formulations in routine is
In, when using with food, the absorption of Ziprasidone increases.This absorption difference that observes in the ziprasidone formulations of routine does not want have.Ziprasidone formulations of the present invention has overcome this problem.
Basically the advantage of having eliminated the dosage form of food effect comprises that patient's convenience strengthens, and has therefore strengthened patient's compliance, because the patient does not need to guarantee that they take this dosage when taking food on the feed or not.This is very important, because follow patient's compliance relatively poor, observes the medical conditions enhancing that Ziprasidone will be treated.
The present invention also comprises the nanoparticle compositions that comprises Ziprasidone, wherein said composition is applied to patient's bioequivalence under the fasting state in compositions being applied to patient under the feed state.
When on the feed with fasting state under when using, the absorption difference of compositions of the present invention is preferably less than about 100%, less than about 95%, less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, or less than about 3%.
In one embodiment of the invention, the present invention includes the compositions that comprises Ziprasidone, wherein said composition is applied to patient under the fasting state and is equivalent to compositions is applied to patient under the feed state, particularly according to the C of U.S. food and drug administration and corresponding European administrative organization (EMEA) guide
MaxDefine with AUC.At the U.S. FDA guide, if AUC and C
MaxThen two kinds of products or method are equivalent (for the purpose of regulating, T between 0.80 to 1.25 in 90% confidence interval (CI)
MaxMeasured value and bioequivalence are irrelevant).According to the two kinds of chemical compounds of guide demonstration of European EMEA or the bioequivalence between the application conditions, the 90%CI of AUC must be between 0.80 to 1.25, C
Max90%CI must be between 0.70 to 1.43.
Nanoparticle compositions of the present invention is to be intended to have beat all, noticeable solubility curve.Preferred Ziprasidone is rapidly-soluble, because dissolved fast more, it is rapid more generally to begin effect, and bioavailability is high more.For solubility curve and the bioavailability of improving Ziprasidone, the dissolving that strengthens Ziprasidone is useful, so that it can reach the level near 100%.
The solubility curve that compositions of the present invention preferably has is: the Ziprasidone at least about 20% in about 5 minutes dissolves.In other embodiments of the present invention, dissolve in about 5 minutes at least about 30% or about 40% Ziprasidone.In other embodiments of the present invention, preferably at least about 40%,,,, or in about 10 minutes, dissolve at least about 80% Ziprasidone at least about 70% at least about 60% at least about 50%.At last, in another embodiment of the invention,,,, or in about 20 minutes, dissolve at least about 100% Ziprasidone at least about 90% at least about 80% preferably at least about 70%.
Preferably in identifiable medium, measure dissolving.For two kinds of very different products of solubility curve in gastric juice, this dissolve medium will produce two very different solubility curves; That is, this dissolve medium can dissolve in the body of prediction group compound.A kind of exemplary dissolve medium is the aqueous medium that comprises the surfactant sodium laurylsulfate of 0.025M.Can carry out determining of meltage by spectrophotography.Can measure dissolving with pivoting leaf method (European Pharmacopoeia).
Another feature of nanoparticle combination of compositions thing of the present invention is, its granule can redispersion, so that this particulate effective mean diameter is that diameter is less than about 2000nm.This is very important, because if this granule can not redispersion so that effectively mean diameter be diameter less than about 2000nm, said composition will be lost owing to general's Ziprasidone wherein is mixed with the benefit that the nanoparticle form obtains so.This is that to comprise Ziprasidone alive particulate than small particle diameter because the nanoparticle compositions is benefited from.If this granule can not become smaller particle size by redispersion after using, because very high surface free energy and the thermodynamic driving force of nanoparticle system can cause free energy totally to reduce, so the granule of their meetings " in bulk " or formation reunion.When these agglomerated particles formed, the bioavailability of this dosage form can greatly be reduced to below the bioavailability that observes in the liquid dispersion form of nanoparticle compositions.
In other embodiments of the present invention, when passing through light scattering method, when microscopy or other suitable methods were measured, redispersion granule of the present invention was (at water, biological dependency medium or any other suitable liquid medium) effective mean diameter be that diameter is less than about 1900nm, less than about 1800nm, less than about 1700nm, less than about 1600nm, less than about 1500nm, less than about 1400nm, less than about 1300nm, less than about 1200nm, less than about 1100nm, less than about 1000nm, less than about 900nm, less than about 800nm, less than about 700nm, less than about 600nm, less than about 500nm, less than about 400nm, less than about 300nm, less than about 250nm, less than about 200nm, less than about 150nm, less than about 100nm, less than about 75nm or less than about 50nm.These methods that are fit to the effective mean diameter of mensuration are that those of ordinary skills are known.
Can measure redispersibility with any proper method known in the art.Referring to the U.S. patent 6 that for example is entitled as " Solid Dose nanoparticle Compositions Comprising aSynergistic Combination of a Polymeric Surface Stabilizer andDioctyl Sodium Sulfosuccinate ", 375,986 embodiment part.
Nanoparticle compositions of the present invention has for example shown noticeable redispersibility behind the human or animal being applied to mammal, this can obtain proof by the reconstruction/redispersion in biological dependency aqueous medium, so that the particulate effective mean diameter of redispersion is that diameter is less than about 2000nm.This biology dependency aqueous medium can be to show the ionic strength of expectation and any aqueous medium of pH, and it has formed the basis of the biological dependency of medium.The pH of expectation and ionic strength be in the physiological condition in the human body representational those.These biological dependency aqueous mediums can be pH and for example aqueous electrolyte solution of ionic strength or aqueous solution or its combinations of any salt, acid or alkali that shows expectation.
Biological dependency pH is well known in the art.For example, the scope of pH is high to 4 or 5 from being slightly less than 2 (but usually greater than 1) under one's belt.In small intestinal, the scope of pH is 4 to 6, and in colon, its scope is 6 to 8.Biological dependency ionic strength also is well known in the art.Under the fasting state ionic strength of gastric juice be about 0.1M and under the fasting state ionic strength of intestinal juice be about 0.14.Referring to, people such as Lindahl for example, " Characterization of Fluidfrim the Stomach and Proximal Jejumum in Men andWomen ", Pharm.Res., 14 (4): 497-502 (1997).It is believed that pH and the ionic strength of being tried solution are more more crucial than concrete chemical contents.Therefore, can obtain suitable pH and ionic strength value by strong acid, highly basic, salt, single or multiple conjugation Acid-Base to a lot of combinations of (that is the corresponding salt of weak acid and this acid), monobasic and multicomponent electrolyte or the like.
Representational electrolyte solution can be, but be not limited to NaCl solution and its mixture of the HCl solution of concentration range about 0.001 to about 0.1N and concentration range about 0.001 to about 0.1M.For example, electrolyte solution can be, but be not limited to about 0.1N or littler HCl, about 0.01N or littler HCl, about 0.001N or littler HCl, about 0.1M or littler NaCl, about 0.01M or littler NaCl, about 0.001M or littler NaCl, and composition thereof.In these electrolyte solutions, because pH and ionic strength conditions be near gastrointestinal tract, 0.01NHCl and/or 0.1M NaCl are the most representative examples of human physiology condition of fasting.
0.001N the electrolyte concentration of HCl, 0.01N HCl and 0.1N HCl corresponds respectively to pH 3, pH 2 and pH 1.Therefore, the 0.01NHCl solutions simulate typical stomach acidity condition.0.1M the solution of NaCl reasonably is similar to whole body, comprises the ionic strength conditions of gastro-intestinal Fluid, although can use the feed condition that surpasses in the concentration of analog people GI road of 0.1M.
The solution of the pH of exemplary demonstration expectation and salt, acid, alkali or its combination of ionic strength includes but not limited to, the sodium of phosphoric acid/phosphate+chlorine, potassium and calcium salt, the sodium of acetic acid/acetate+chlorine, potassium and calcium salt, the sodium of carbonate+chlorine, potassium and calcium salt, and the sodium of citric acid/citrate+chlorine, potassium and calcium salt.
As mentioned above, said composition also comprises at least a surface stabilizer.This surface stabilizer can adsorb, or is attached to the particle surface that comprises Ziprasidone.Preferably, this surface stabilizer preferably adsorbs or is connected to particulate surface, rather than with granule or with other surface-stable agent molecule generation chemical reactions.The molecule of each absorption of this surface stabilizer does not have intermolecular interconnection basically.
It is extensively different being present in the Ziprasidone of combination species of the present invention and the relative quantity of surface stabilizer.The optional amount of each component can depend on, surface tension of for example selected among other things concrete medicine, hydrophilic-lipophilic balance (HLB), fusing point and stabilizing agent aqueous solution or the like.Based on total mixed weight of Ziprasidone and surface stabilizer, and do not comprise other excipient, ziprasidone concentration can be different, and from about 99.5% to about 0.001%, about 95% to about 0.1% or about 90% to about 0.5 weight %.Based on total mixing dry weight of Ziprasidone or its salt or derivant and surface stabilizer, and do not comprise other excipient, the concentration of surface stabilizer can be different, and from about 0.5% to about 99.999%, about 5.0% to about 99.9% or about 10% to about 99.5 weight %.
For Ziprasidone, the selection of surface stabilizer is not footy, requires to test widely to make required preparation.Therefore, the present invention relates to beat all discovery: can prepare the nanoparticle compositions that comprises Ziprasidone.
Can use the combination of more than one surface stabilizer in the present invention.The useful surface stabilizer that can use in the present invention includes but not limited to, known organic and inorganic drug excipient.These excipient comprise various polymer, low-molecular-weight oligomer, natural product and surfactant.Surface stabilizer comprises nonionic, anion, cation, ion and zwitterionic surfactant.
The representative example of surface stabilizer comprises hydroxypropyl emthylcellulose (now being called hypromellose), hydroxypropyl cellulose, polyvinylpyrrolidone, sodium laurylsulfate, the dioctyl sulfosuccinate, gelatin, casein, lecithin (phospholipid), glucosan, arabic gum, cholesterol, the tragakanta, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, the octadecanol hexadecanol, cetomacrogol emulsifying wax, sorbitan ester, polyoxyethylene alkyl ether (for example, polyglycol ether is cetomacrogol 1000 for example), castor oil derivatives, polyoxyethylene sorbitan fatty acid ester is (for example, commercially available
For example, Tween
And Tween
(ICI Speciality Chemicals)); Polyethylene Glycol (for example, Carbowaxs
With
(Union Carbide)), Myrj 45, silicon dioxide colloid, phosphate, carboxymethylcellulose calcium, sodium carboxymethyl cellulose, methylcellulose, hydroxyethyl-cellulose, hydroxypropyl methyl O-phthalic acid cellulose, non-microcrystalline Cellulose, aluminium-magnesium silicate, triethanolamine, polyvinyl alcohol (PVA), 4-(1,1,3, the 3-tetramethyl butyl)-polymer (being also referred to as tyloxapol, superione and triton), poloxamer (for example, the Pluronics of phenol and oxirane and formaldehyde
With
They are block copolymers of oxirane and expoxy propane); Poloxamines (for example, Tetronic
Be also referred to as Poloxamine
Be to add expoxy propane and oxirane continuously and the four-functional group block copolymer that obtains (BASF Wyandotte Corporation, Parsippany, NJ.)) to aminophylline; Teronic
(T-1508) (BASF Wyandotte Corporation), Tritons X-
It is alkyl aryl polyether sulfonate (Rohm and Haas); Crodestas F-
It is the mixture (Croda Inc.) of sucrose stearate and sucrose distearate; Right-different Nonylphenoxy gathers-((+)-2,3-Epoxy-1-propanol), is also referred to as Olin-
Or Surfactant 10-
(OHn Chemicals, Stamford, CT); Crodestas SL-
(Croda, Inc.); And SA9OHCO, it is C
18H
37CH
2(CON (CH
3)-CH
2(CHOH)
4(CH
2OH)
2(Eastman Kodak Co.); Capryl-N-methyl glucoside amine; Positive decyl β-D-pyranglucoside; Positive decyl β-D-pyrans maltoside; Positive lauryl β-D-pyranglucoside; Positive lauryl β-D-maltoside; Heptanoyl group-N-methyl glucoside amine; N-heptyl-β-D-pyranglucoside; N-heptyl β-D-thioglycoside; N-hexyl β-D-pyranglucoside; Pelargonyl group-N-methyl glucoside amine; Pelargonyl group β-D-pyranglucoside; Caprylyl-N-methyl glucoside amine; N-octyl-β-D-pyranglucoside; Octyl group β-D-pyrans thioglycoside; Randomcopolymer of PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, lysozyme, vinylpyrrolidone and vinyl acetate or the like.
The ion of useful cationic surface stabilizing agent includes but not limited to, polymer, biopolymer, polysaccharide, cellulose family, alginate, phospholipid and non-polymerization chemical compound, amphoteric ion type stabilizing agent for example, poly--the n-picoline, chlorination anthryl pyridine, cationic phospholipid, chitosan, polylysine, polyvinyl imidazole, polybrene, Diethylaminoethyl acrylic acid poly-methyl ester trimethylammonium bromide (PMMTMABr), hexyl desyl,a-phenyl phenacyl trimethylammonium bromide (HDMAB) and polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate.
Other useful cationic stabilized agent include but not limited to, cation lipid, sulfonium, Phosphonium and quaternary ammonium compound, for example stearyl trimethyl ammonium chloride, benzyl-two (2-chloroethyl) ethyl ammonium bromide, Cortex cocois radicis trimethyl chlorine or bromine ammonium, Cortex cocois radicis methyl dihydroxy ethyl chlorine or bromine ammonium, decyl triethyl ammonium chloride, decyl dimethyl hydroxyl ethyl chloride or ammonium bromide, C
12-15Dimethyl hydroxyl ethyl chloride or ammonium bromide, Cortex cocois radicis dimethyl hydroxyl ethyl chloride or ammonium bromide, myristyl trimethyl ammonium methylsulfuric acid ester, lauryl dimethyl benzyl chloride or ammonium bromide, lauryl dimethyl (ethyleneoxy)
4Chlorine or bromine ammonium, N-alkyl (C
12-18) dimethyl benzyl ammonium chloride, N-alkyl (C
14-18) dimethyl-benzyl ammonium chloride, N-myristyl dimethyl benzyl ammonium chloride monohydrate, dimethyl didecyl ammonium chloride, N-alkyl and (C
12-14) dimethyl 1-naphthyl methyl ammonium chloride, trimethyl-ammonium halide, alkyl-leptodactyline and dialkyl group-dimethyl ammonium, lauryl trimethyl ammonium chloride, ethoxylated alkyl amidoalkyl dialkyl ammonium salt and/or ethoxylation trialkyl ammonium salts, dialkyl benzene dialkylammonium chloride, N-DDAC, N-myristyl dimethyl benzyl ammonium chloride monohydrate, N-alkyl (C
12-14) dimethyl 1-naphthyl methyl ammonium chloride and lauryl dimethyl benzyl ammonium chloride, dialkyl benzene alkyl ammomium chloride, lauryl trimethyl ammonium chloride, alkyl benzyl ammonio methacrylate, alkyl benzyl dimethyl ammonium bromide, C
12, C
15, C
17Trimethylammonium bromide, lauryl benzyltriethylammoinium chloride, poly--diallyldimethylammonium chloride (DADMAC), alkyl dimethyl ammonium chloride, alkyl dimethyl ammonium halide, hexatriacontane ylmethyl ammonium chloride, decyl trimethylammonium bromide, lauryl triethyl group ammonium bromide, four decyl trimethylammonium bromides, (ALIQUAT 336 for methyl trioctylphosphine ammonium chloride
TM), POLYQUAT 10
TM, tetrabutyl ammonium bromide, benzyltrimethylammonium bromide, cholinester (for example cholinester of fatty acid), benzalkonium chloride, the stearic alkane ammonium compounds (for example stearoyl three monium chlorine and distearyl two monium chlorine) of chlorination, bromine or cetylpyridinium chloride, halogeno salt, the MIRAPOL of oxozone ethyl alkylamine
TMWith ALKAQUA T
TM(AlkarilChemical Company), Fixanol; Amine, for example alkylamine, dialkylamine, alkanoyl amine, polyethylenepolyamine, N, N-dialkyl amino alkyl acrylate and vinylpyridine, amine salt be acetic acid lauryl amine, stearylamine acetate, Fixanol and alkyl imidazole salt and amine oxide for example; Acid imide azolinium salt; Protonated tetrapropylene amide; Methylated tetravalence polymer, for example poly-[diallyldimethylammonium chloride] and poly--[N-ethylene methacrylic yl pyridines chlorine]; And cation guar gum.
These exemplary cationic surface stabilizing agents and other useful cationic surface stabilizing agents are at J.Cross and E.Singer, Cationic Surfactants:Analytical and Biological Evaluation (Marcel Dekker, 1994); P. and D.Rubingh (Editor), Cationic Surfactants:Physical Chemistry (MarcelDekker, 1991); And J.Richmond, Cationic Surfactants:OrganicChemistry is described in (Marcel Dekker, 1990).
The non-polymerization surface stabilizer is non-polymeric arbitrarily type chemical compound, for example the organic compound, phosphonium compounds of benzalkonium chloride, positively charged, oxygen compound, halogen compound, cation organo-metallic compound, tetravalence phosphorus compound, pyridine compounds, aniline compound, ammonium compounds, hydroxyl ammonium compounds, uncle's ammonium compounds, secondary ammonium compounds, tertiary amine chemical compound and structural formula NR
1R
2R
3R
4 (+)Quaternary ammonium compound.For structural formula NR
1R
2R
3R
4 (+)Chemical compound:
(i) R
1-R
4Not CH
3
(ii) R
1-R
4In one be CH
3
(iii) R
1-R
4In three be CH
3
(iv) R
1-R
4All be CH
3
(v) R
1-R
4In two be CH
3, R
1-R
4In one be C
6H
5CH
2, and R
1-R
4In one be 7 or the alkyl chain of carbon atom still less;
(vi) R
1-R
4In two be CH
3, R
1-R
4In one be C
6H
5CH
2, and R
1-R
4In one be the alkyl chain of 19 or more a plurality of carbon atoms;
(vii) R
1-R
4In two be CH
3, R
1-R
4In one be group C
6H
5(CH
2)
n, n>1 wherein;
(viii) R
1-R
4In two be CH
3, R
1-R
4In one be C
6H
5CH
2And R
1-R
4In one comprise at least one hetero atom;
(ix) R
1-R
4In two be CH
3, R
1-R
4In one be C
6H
5CH
2And R
1-R
4In one comprise at least one halogen;
(x) R
1-R
4In two be CH
3, R
1-R
4In one be C
6H
5CH
2And R
1-R
4In one comprise at least one ring plate section;
(xi) R
1-R
4In two be CH
3, R
1-R
4One among the x is phenyl ring; Or
(xii) R
1-R
4In two be CH
3, R
1-R
4In two be pure fatty fragment.
These chemical compounds include but not limited to, behenalkonium chloride, benzethonium chloride, cetylpyridinium chloride Yu chlorination triamine, lauralkonium chloride, cetalkonium chloride, cetrimonium bromide, cetrimonium chloride, cethylamine hydrofluoride, chlorallylmethenaminechloride (Quateraium-15), distearyl trimethyl ammonium chloride (Quaternium-5), lauryl dimethyl ethylbenzylammonium chloride (Quaternium-14), Quaternium-22, Quaternium-26, Quaternium-18 hectorite, hydrochloric acid dimethyl aminoethyl chlorine, cysteine hydrochloride, the oily ether phosphate of diethanol ammonium POE (10), the oily ether phosphate of diethanol ammonium POE (3), chlorination tallow benzene diformazan hydrocarbon ammonium, dimethyl two hot decyl ammonium bentonite, stearyl chloride, Bradosol Bromide, denatonium benzoate, the myristyl dimethyl benzyl ammonium chloride, Dodecyl trimethyl ammonium chloride, ethylenediamine dihydrochloride, guanidine hydrochloride, pyridoxine hydrochloride, iofetamine hydrochloride, the hydrochloric acid meglumine, methylbenzethonium chloride, the myristyl trimethylammonium bromide, the oil base trimethyl ammonium chloride, polyquaternary ammonium salt-1, procaine hydrochloride, the Cortex cocois radicis betanin, the oronain bentonite draws in department, the oronain hectorite draws in department, two hydrofluorination stearoyl trihydroxy ethyl trimethylene diamines, Adeps Bovis seu Bubali base trimethyl ammonium chloride and six decyl trimethylammonium bromides.
Surface stabilizer is commercially available and/or can prepares by technology known in the art.Most surface stabilizer is the known drug excipient, and in the theHandbook of Pharmaceutical Excipients that the AmericanPharmaceutical Association and The Pharmaceutical Society ofGreat Britain (The Pharmaceutical Press, 2000) co-publicate, be described in detail.
Except Ziprasidone, compositions of the present invention can comprise one or more chemical compounds that is used for the treatment of schizophrenia or similar mental disorder and associated conditions.Said composition also can be co-administered with this chemical compound.These other reactive compounds preferably include be used for the treatment of the health disease for example have a headache, generate heat, painful or generally by schizophrenia and similar those chemical compounds of other similar conditions of causing of psychiatric disturbance.These reactive compounds should determine that it can not disturb the mode of the therapeutic effect of Ziprasidone to exist with those skilled in the art.
Compositions of the present invention also can comprise one or more binding agents, filler, diluent, lubricant, emulsifying agent and suspending agent, sweeting agent, flavoring agent, antiseptic, buffer agent, wetting agent, disintegrating agent, foaming agent, aromatic and other excipient.These excipient are known in the art.In addition, various antibiotic for example parabens, chlorobutanol, phenol, sorbic acid or the like can guarantee to stop microbial growth with antifungal by adding.When using in injectable formulation, said composition can comprise isotonic agent for example sugar, sodium chloride or the like, and postpones reagent that the injectable drug dosage form absorbs for example aluminum monostearate and gelatin.
The example of filler is lactose monohydrate, Lactis Anhydrous and various starch; The example of binding agent be various starch and crospolyvinylpyrrolidone, microcrystalline Cellulose for example
PH101 and
Microcrystalline Cellulose (the ProSolvSMCC of PH 102, microcrystalline Cellulose and silication
TM).
Suitable lubricant comprises that influence wants the reagent of the flowability of pressed powder, be silicon dioxide for example
200, Talcum, stearic acid, magnesium stearate, calcium stearate and silica gel.
The example of sweeting agent is any natural or synthetical sweeting agent, for example sucrose, xylitol, saccharin sodium, cyclamate, aspartame and acesulfame.The example of flavoring agent is
(trade mark is MAFCO), bubble gum flavor, flavoring agent of fruit etc.
Examples of preservatives is other esters butoben, alcohol second or benzylalcohol, phenolic compound phenol for example for example for example of potassium sorbate, methyl hydroxybenzoate, propylparaben, benzoic acid and salt thereof, P-hydroxybenzoic acid, or quaternary ammonium compound benzalkonium chloride for example.
The suitable dilution agent comprises the acceptable inert filler of pharmacy, for example the mixture of microcrystalline Cellulose, lactose, Bibasic Calcium Phosphate, sugar and/or any above-mentioned substance.The example of diluent comprises that microcrystalline Cellulose for example
PH101 and
PH102; Lactose for example lactose monohydrate, Lactis Anhydrous and
DCL21; Bibasic Calcium Phosphate for example
Mannitol; Starch; Sorbitol; Sucrose; And glucose.
Suitable disintegrating agent comprises slight crosslinked polyvinylpyrrolidone, corn starch, potato starch, corn starch and modified starch, cross-linking sodium carboxymethyl cellulose, crospovidone, primojel and their mixture.
The example of foaming agent is that foaming is to for example organic acid plus carbonate or bicarbonate.Suitable organic acid comprises, for example lactic acid, tartaric acid, malic acid, Fumaric acid, adipic acid, succinic acid and alginic acid and anhydride and hydrochlorate.Suitable carbonate and bicarbonate comprise, for example sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate and arginine carbonate.Alternately, can only there be the right sodium bicarbonate component of foaming.
Compositions of the present invention can comprise carrier, adjuvant or inert matter (hereinafter, being referred to as " carrier ").
Can for example use, grinding, homogenize, precipitation, lyophilizing or plate emulsifying technology prepare this nanoparticle compositions.The illustrative methods of preparation nanoparticle compositions is described in ' 684 patents.The illustrative methods of preparation nanoparticle compositions has also been described: patent 5,518,187 in following document; 5,718,388; 5,862,999; 5,665,331; 5,662,883; 5,560,932; 5,543,133; 5,534,270; 5,510,118; With 5,470,583.
In a method, the Dispersion of Particles that will comprise Ziprasidone is in the liquid dispersion medium of Ziprasidone indissoluble.In the presence of abrasive media, use mechanical means particle diameter to be decreased to the effective mean diameter that needs then.Disperse medium can be, for example, and water, safflower oil, ethanol, the tert-butyl alcohol, glycerol, Polyethylene Glycol (PEG), hexane or ethylene glycol.Preferred disperse medium is a water.Can in the presence of at least a surface stabilizer, reduce particulate size.The granule that can will comprise Ziprasidone after grinding contacts with one or more surface stabilizers.In reducing the process of its particle diameter, can in Ziprasidone/surface stabilizer compositions, add other chemical compounds, for example diluent.Can prepare dispersion continuously or in a batch mode.It will be understood to those of skill in the art that in this case after grinding, not every granule all can be decreased to the size that needs.In this case, can isolate the granule with required size and be used to implement the present invention.
The another kind of method that forms the nanoparticle compositions that needs is the microprecipitation method.This is a kind of method for preparing the stabilising dispersions of slightly solubility Ziprasidone in the presence of surface stabilizer and one or more colloid-stabilised enhancing surfactants and when not comprising the toxic solvents of any trace or soluble beavy metal impurity.This method comprises that for example: (1) is dissolved in Ziprasidone in the appropriate solvent; (2) in the solution that comprises at least a surface stabilizer, add the preparation of step (1); (3) with the preparation of suitable non-solvent settling step (2).If exist, can be after this method by dialysis or diafiltration and concentrate this dispersion by conventional method and remove formed whole salt.
Also can be equipped with the nanoparticle compositions by the homogenize legal system.Exemplary homogenize method is in U.S. patent 5,510,118, is entitled as in " Process of Preparing Therapeuticcompositions Containing Nanoparticles " to be described.This method comprises the Dispersion of Particles that will comprise Ziprasidone in liquid dispersion medium, and this dispersion of homogenize is decreased to described particle diameter the effective mean diameter that needs then.Can in the presence of at least a surface stabilizer, reduce particulate size.Can before or after grinding, this granule be contacted with one or more surface stabilizers.Reduce its particle diameter cross the Cheng Qian, in or after, can in said composition, add other chemical compounds, for example diluent.Can prepare dispersion continuously or in a batch mode.
The another kind of method that forms the nanoparticle compositions that needs is that spraying is lyophilized into liquid (SFL).This method comprises that the organic or organic aqueous solution with Ziprasidone and surface stabilizer is expelled in cooling liquid style such as the liquid nitrogen.To be enough to the making speed of crystallization and germination minimum freeze the microdroplet that this comprises ziprasidone solution, formed the granule of nano-architecture like this.According to selected solvent system and treatment conditions, this granule can have different particle shapes.In separating step, avoiding removing denitrification and solvent under particle aggregation or the sophisticated condition.
As the compensation process of SFL, also can form equivalent nano-architecture granule with ultrafast lyophilization (URF) with the surface area that extremely increases.URF comprise take Ziprasidone with mixable, anhydrous, organic or organic aqueous solution of water and surface stabilizer, on the substrate that is applied to lower the temperature.Remove by for example lyophilizing or atmosphere lyophilization then and desolvate the granule of remaining resulting nanoparticle structure.
The another kind of method that forms the nanoparticle compositions that needs is the plate emulsion process.The plate emulsion process is prepared the granule of the nano-architecture with controlled particle size distribution and quick dissolution properties.This method comprises prepares oil-in-water emulsion, then with the non-aqueous solution swelling that comprises Ziprasidone and surface stabilizer.This particle grain size distribution is the direct result of Emulsion droplet size before being written into the Emulsion that comprises medicine.This particle diameter is controlled and optimizes in this process.In addition, by selecting to use solvent and stabilizing agent, in the stability that does not have or suppress to have realized under the Ostwald ripening Emulsion.Subsequently, remove and desolvate and water, recover stable nano-architecture granule.Can realize different particle shapes by control treatment condition suitably.
The invention provides a kind of method, comprise the nanoparticle compositions that comprises Ziprasidone of using effective dose.
Compositions of the present invention (for example can be mixed with parenteral, vein, intramuscular or subcutaneous), oral (for example solid, liquid or aerosol form, vagina), in intranasal, rectum, ear, eye, part (for example, powder, ointment or drop), containing, the brain pond, intraperitoneal or local application etc.
This nanoparticle compositions can be used with solid or liquid dosage form, for example liquid dispersion, gel, aerosol, ointment, long-acting medicament, emulsifiable paste, sustained release preparation, fast melt preparation, lyophilized formulations, tablet, capsule, delayed release preparation, prolongation delivery formulations, pulsed delivery formulations, mixed type discharges immediately and sustained release preparation or the like.
The compositions that is fit to the parenteral injection can comprise the acceptable sterile aqueous of physiology or non-aqueous solution, dispersion liquid, suspension or Emulsion, with the sterilized powder that can remake into sterile injectable solution or dispersion liquid.The example of suitable aqueous or non-aqueous carrier, diluent, solvent or inert matter comprises for example ethyl oleate of water, ethanol, polyhydric alcohol (propylene glycol, Polyethylene Glycol, glycerol or the like), its suitable mixture, vegetable oil (for example olive oil) and injectable organic ester.Can be for example by using for example lecithin of coating, by in dispersion liquid, keeping the particle diameter that needs and by using surfactant to keep suitable flowability.
Oral solid dosage forms includes but not limited to, capsule, tablet, pill, powder and granule, this solid dosage forms can be for example melt preparation, sustained release preparation, lyophilized preparation, delayed release preparation, prolongation delivery formulations, pulsed delivery formulations fast, mixed type discharges immediately and sustained release preparation or its combination.Preferred solid tablet.In these solid dosage formss, activating agent mixes with at least a following material: (a) one or more inert excipients (or carrier), for example sodium citrate or dicalcium phosphate; (b) filler or extender, for example starch, lactose, sucrose, glucose, mannitol and silicic acid; (c) binding agent, for example carboxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and arabic gum; (d) wetting agent, for example glycerol; (e) disintegrating agent, for example agar, calcium carbonate, Rhizoma Solani tuber osi or tapioca, alginic acid, some composition silicate and sodium carbonate; (f) solution retarder paraffin for example; (g) absorption enhancer, for example quaternary ammonium compound; (h) wetting agent, for example hexadecanol and glyceryl monostearate; (i) adsorbent, for example Kaolin and bentonite; (j) lubricant, for example Talcum, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium laurylsulfate or its mixture.For capsule, tablet and pill, this dosage form also can comprise buffer agent.
Oral liquid dosage form comprises the acceptable Emulsion of pharmacy, solution, suspension, syrup and elixir.Except Ziprasidone, liquid dosage form can comprise this area inert diluent commonly used, for example water or other solvents, solubilizing agent and emulsifying agent.Exemplary emulsifying agent is ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzylalcohol, benzyl benzoate, propylene glycol, 1,3-butanediol, dimethyl formamide, oil is Oleum Gossypii semen for example, Oleum Arachidis hypogaeae semen, maize embryo oil, olive oil, the fatty acid ester of Oleum Ricini and Oleum sesami, glycerol, tetrahydrofurfuryl alcohol, Polyethylene Glycol, sorbitan or mixture of these materials or the like.
Those of ordinary skill will be understood that, can rule of thumb come to determine the treatment effective dose of Ziprasidone.The actual dose level of Ziprasidone can be different in nanoparticle compositions of the present invention, so that the amount of this medicine that obtains can be replied for the treatment that concrete compositions and application process need to obtain effectively.Therefore, selected dosage level depends on the effectiveness of the therapeutic effect, route of administration of needs, the Ziprasidone used, required treatment persistent period and other factors.
Units dosage composition can comprise Ziprasidone or its about quantity of this tittle, can be used to constitute dosage every day.But, should be understood that any concrete patient's concrete dosage level depends on various factors: the cell that reach or the type of physiologic response and degree; The concrete reagent of being used or the activity of compositions; Employed concrete reagent or compositions; Patient's age, body weight, general health, sex and diet; The time of using of Ziprasidone, route of administration and excretion rate; The persistent period of treatment; With Ziprasidone associating or the reactive compound that uses simultaneously; And the known similar factor of field of medicaments.
II. the sustained release compositions that comprises Ziprasidone
The effectiveness of pharmaceutical compound in prevention and treatment morbid state depends on several factors, comprises the speed and the persistent period of sending chemical compound from dosage form to the patient.Given dosage form shows in the patient delivery rate and the combination of persistent period can be described as release profiles in its body, and according to the pharmaceutical compound of being used, it is relevant with blood plasma Chinese materia medica compound concentrations and persistent period.Because the speed of pharmacokinetic property biological example availability, absorption and the elimination of pharmaceutical compound changes, so release profiles and resulting curve of blood plasma have become the factor of thinking very important to designed effective treatment.
The release profiles of dosage form can demonstrate different rates of release and persistent period, can be continuous or pulse.The release profiles that successive release profiles comprises is that wherein a certain amount of one or more pharmaceutical compounds discharge continuously with constant or variable speed during whole dosing interval.The release profiles that the pulse release curve comprises is, wherein one or more pharmaceutical compounds of at least two discontinuous quantities are with different speed and/or discharge in differing time frames.For any given pharmaceutical compound or these combination of compounds, the release profiles of given dosage form has produced relevant curve of blood plasma in the patient.When two or more components of dosage form had different release profiles, it was the combination of individual release profiles that the release profiles of this dosage form is done as a whole, can be described as " multimodal ".Wherein release profiles with two-component dosage form of different release profiles of every kind of component can be described as " bimodal ", and wherein release profiles with three-component dosage form of different release profiles of every kind of component can be described as " three peaks ".
With the variable class that can be applicable to release profiles seemingly, patient's relevant curve of blood plasma has shown the plasma concentration level that pharmaceutical compound is constant or variable in the persistent period of effect, can be continuously or pulse.Successive release profiles comprises that all show peaked speed of single plasma concentration and the curve of blood plasma of persistent period.The curve of blood plasma that the pulse curve of blood plasma comprises is that wherein at least two higher plasma concentration levels of pharmaceutical compound are separated by lower plasma concentration level, can be described as " multimodal ".The pulse curve of blood plasma that shows two peaks can be described as " bimodal ", shows that the pulse curve of blood plasma at three peaks can be described as " three peaks ".According to, to the release profiles of small part according to individual components in the pharmacokinetics of the pharmaceutical compound that comprises in the dosage form and the dosage form, multimodal discharges.
In one embodiment, the invention provides granose change release composition, the nanoparticle that it is sent Ziprasidone or comprise Ziprasidone with pulse mode.This nanoparticle is a above-mentioned type, and comprises at least a surface stabilizer simultaneously.
In another embodiment, the invention provides granose change release composition, the nanoparticle that it is sent Ziprasidone in a continuous manner or comprises Ziprasidone.This nanoparticle is a above-mentioned type, and comprises at least a surface stabilizer simultaneously.
In another embodiment, the invention provides a kind of granose change release composition, wherein the Ziprasidone of first or the nanoparticle that comprises Ziprasidone discharge after using immediately, and the Ziprasidone of one or more further parts or the nanoparticle that comprises Ziprasidone postpone the back at initial time and discharge.
In another embodiment, the invention provides and use a kind of every day 1 time or use 2 times solid oral dosage form every day, comprise granose change release composition of the present invention.
In another embodiment, the invention provides a kind of method that prevents and/or treats schizophrenia and similar psychiatric disturbance, comprise and use compositions of the present invention.
In one embodiment, the invention provides a kind of granose change release composition, wherein forming granose granule is the nanoparticle granule of the above-mentioned type.When needs, this nanoparticle granule comprises change and discharges coating and/or change the release matrix material.
According to an aspect of the present invention, a kind of pharmaceutical composition is provided, have and comprise particulate first component that contains active component and comprise particulate at least one subsequent component that contains active component, every kind of subsequent component has rate of release and/or the persistent period different with first component, and wherein at least a described component comprises the granule that contains Ziprasidone.In one embodiment of the invention, form the nanoparticle granule that the granose granule that comprises Ziprasidone itself comprises the above-mentioned type, wherein this nanoparticle granule comprises Ziprasidone and also comprises at least a surface stabilizer.In another embodiment of the invention, the nanoparticle granule that comprises Ziprasidone and also comprise the above-mentioned type of at least a surface stabilizer itself is the granose granule that comprises medicine.The granule that comprises medicine can wrap quilt with changing the coating that discharges.Alternately or additionally, the granule that comprises medicine can comprise and changes the stroma ground substance that discharges.Behind oral delivery, send Ziprasidone with pulse mode or comprise the nanoparticle of Ziprasidone in said composition.In one embodiment, first component provides Ziprasidone that discharges immediately or the nanoparticle that comprises Ziprasidone, and one or more subsequent component provide the nanoparticle that changes the Ziprasidone that discharges or comprise Ziprasidone.In these embodiments, immediate-release component has the shortlyest promoted effect by making from being administered to the time of treatment between the effective plasma concentration level, one or more subsequent component can be used to make the change minimum of plasma concentration level, and/or keep the effective plasma concentration of treatment in whole dosing interval.
Change to discharge coating and/or change that particulate active component that the release matrix material can cause first to comprise active component discharges and the particulate active component that comprises active component of further part has a lag time between discharging.When a granule that comprises active component more than the part provided change to discharge, change release coating and/or change release matrix material had caused between the release of the particulate active component that comprises active component of different piece a lag time being arranged.By regulating the composition that changes composition and/or the amount that discharges coating and/or change employed change release matrix material and/or measuring the persistence length that changes these lag times.Therefore, the persistence length of lag time can be designed for the required curve of blood plasma of simulation.
Because change curve of blood plasma that release composition produces and be substantially similar to twice of continuous administration or the curve of blood plasma that produces of IR dosage form repeatedly using the back, therefore change release composition of the present invention is useful especially for using Ziprasidone.
According to another aspect of the present invention, said composition can be designed for the generation curve of blood plasma, and it makes and twice of continuous administration or the repeatedly minimum or disappearance of change of the relevant plasma concentration level of IR dosage form.In these embodiments, said composition can have immediate-release component with by making from being administered to the time of treatment between the effective plasma concentration level the shortest and facilitation, and has at least a change and discharge component to keep the effective plasma concentration level of treatment in whole dosing interval.
Active component in every kind of component can be identical or different.For example, compositions can comprise and only contains Ziprasidone or contain the component of the nanoparticle of Ziprasidone as active component.Alternately, compositions can comprise first component that contains Ziprasidone or contain the nanoparticle of Ziprasidone, contain Ziprasidone or contain the subsequent component with the co-administered active component of Ziprasidone of being fit to beyond the nanoparticle of Ziprasidone with at least a, perhaps contain Ziprasidone or contain first component and at least a subsequent component that contains Ziprasidone or contain the nanoparticle of Ziprasidone of the active component beyond the nanoparticle of Ziprasidone.Really, when mutual when compatible between the active component, two or more active component can be incorporated in the same composition.The active component that exists in a component of said composition can be attended by, and for example enhancing chemical compound in another component of said composition or enhanced sensitivity chemical compound are to change its bioavailability or therapeutic effect.
Term used herein " reinforcing agent " be meant a kind of energy by promote animal for example among the people by the clean output of GIT the absorption of enhanced activity composition and/or the chemical compound of bioavailability.Reinforcing agent includes but not limited to medium-chain fatty acid; Its salt, ester, ether and derivant comprise glyceride and triglyceride; Nonionic surfactant is for example by those of oxirane and fatty acid, aliphatic alcohol, alkyl phenol or sorbitan or fatty acid glyceride prepared in reaction; Cytochrome P 450 inhibitors, P-glycoprotein inhibitors or the like; And two or more mixture in these reagent.
Exist therein in those embodiments of the component that comprises more than one medicines, dosage regimen as required, the ratio of the Ziprasidone that comprises in every kind of component can be identical or different.The Ziprasidone that exists in first component and subsequent component can be any amount that is enough to produce the effective plasma concentration level of treatment.But when the time spent, Ziprasidone can exist with optical voidness stereoisomer basically or as mixture, the racemic mixture of two or more stereoisomers.Ziprasidone preferred amount in compositions is about 0.1 to about 500mg.In another embodiment, Ziprasidone preferred amount in compositions is about 1 to about 100mg.In another embodiment, the amount of Ziprasidone in first component is about 0.5 to about 60mg; In another embodiment, the amount of Ziprasidone in first component preferably about 2.5 to about 30mg.If be present in the subsequent component, the amount of Ziprasidone with the described similar scope of first component in.
The time release characteristic of sending Ziprasidone from each component can change by the composition that changes every kind of component, comprises existing arbitrarily excipient of change and/or coating.Especially, if there is coating, can discharge the composition of coating and/or the release that amount is controlled Ziprasidone by the change that changes on the granule.If exist more than a kind of change to discharge component, the change of each in these components discharges coating can be identical or different.Similarly, bring about changes when discharging, can pass through the selection of the change release matrix material used and the release that amount is controlled active component when change the release matrix material by embedding.It can be to measure arbitrarily that the change that exists in every kind of component discharges coating, as long as it is enough to make every kind of concrete component to obtain the time delay of needs.It can be to measure arbitrarily that the change that exists in every kind of component discharges coating, as long as it is enough to make the lag time that obtains needs between the component.
The lag time and/or the time delay that discharge Ziprasidone from every kind of component also can change by the composition that changes every kind of component, comprise excipient and coating that change may exist arbitrarily.For example, first component can be an immediate-release component, and wherein Ziprasidone discharges immediately after using.Alternately, first component can be the immediate-release component of time delay for example, and wherein Ziprasidone all discharges immediately basically after postponing a period of time.Second and subsequent component can be the immediate-release component of described time delay for example as just, or alternately, the lasting release of time delay or prolong and discharge component, wherein Ziprasidone time of going through prolongation with controllable mode discharges.
It will be understood to those of skill in the art that the exact nature of plasma concentration curve can be subjected to the influence of the combination of all above-mentioned factors.Especially, each lag time of sending between (and therefore also beginning effect) that comprises the Ziprasidone in the component of Ziprasidone can be controlled by the composition and the coating (if existence) that change every kind of component.Therefore, the composition (amount and the character that comprise active component) by changing every kind of component and by changing lag time can obtain a lot of release and curve of blood plasma.According to from every kind of component, discharge the character (promptly discharge immediately, continue to discharge or the like) that lag time length between the Ziprasidone and Ziprasidone discharge from every kind of component, curve of blood plasma can be successive (promptly, have single maximum) or wherein can in curve of blood plasma, separate well and clear (for example the definition, when time delay than long time) or the pulse at the peak of high superposed (for example, when time delay more in short-term).
When not needing to use two or more dosage device, use the single dosage device that comprises compositions of the present invention and the curve of blood plasma that produces is favourable when the two or more pulses that need delivering active ingredients.
Can use in required mode and change any coating substance that Ziprasidone discharges.Especially, the coating substance that is adapted at implementing using when of the present invention includes but not limited to the polymeric coatings material, for example Cellacefate, acetic acid three maleic acid celluloses, hydroxypropyl methyl O-phthalic acid cellulose, Opaseal, ammonio methacrylate copolymer are for example with trade mark
With RL sells those, polyacrylic acid and polyacrylate and methacrylate copolymer are for example with trade mark
With L sells those, polyethylene acetal diethylamino acetas, hydroxypropyl methyl cellulose acetate succinate, Lac; Hydrogel with become the glue material; for example carboxy vinyl polymer, sodium alginate, sodium carboxymethyl cellulose, carboxymethylcellulose calcium, carboxymethyl starch sodium, polyvinyl alcohol, hydroxy ethyl cellulose, methylcellulose, gelatin, starch and based on cellulosic cross linked polymer-wherein the degree of cross linking is so low so that can promote the absorption of water and the expansion of polymeric matrix, hydroxypropyl cellulose, hydroxypropyl emthylcellulose, polyvinylpyrrolidone, crosslinked starch, microcrystalline Cellulose, chitin, aminoacyl-methacrylic acid copolymer (
-PM, Rohm ﹠amp; Haas), pullulan, collagen, casein, agar, arabic gum, sodium carboxymethyl cellulose, (swellable hydrophilic polymer) gather (hydroxyalkyl methacrylic acid) (the about 5k-5 of mol.wt., 000k), polyvinylpyrrolidone (the about 10k-360k of mol.wt.), anion and cationic water gel, polyvinyl alcohol with rudimentary acetic acid residue, the swellable mixture of agar and carboxymethyl cellulose, maleic anhydride and cinnamic copolymer, ethylene, propylene or isobutene., pectin (the about 30k-300k of mol.wt.), polysaccharide is agar for example, arabic gum, karaya, the tragakanta, algin and guar gum, polyacrylamide;
Poly(ethylene oxide) (the about 100k-5 of mol.wt., 000k),
The diester of acrylate polymer, glucosan, the pure and mild poly N-vinyl-2-Pyrrolidone of crosslinked polyethylene, glucoamylase sodium are (for example
Edward Mandell C.Ltd.); Hydrophilic polymer, for example polysaccharide, methylcellulose, sodium carboxy methyl cellulose or calcium, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, hydroxy ethyl cellulose, NC Nitroncellulose, carboxy methyl cellulose, cellulose ether, poly(ethylene oxide) are (for example,
UnionCarbide), the copolymer of methylethylcellulose, ethylhydroxyethylcellulose, cellulose acetate, cellulose butyrate, cellulose propionate, gelatin, collagen, starch, maltodextrin, pullulan, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, fatty acid glyceride, polyacrylamide, polyacrylic acid, methacrylic acid or methacrylic acid are (for example
Rohm and Haas), other acrylic acid derivative, sorbitan ester, natural gum, lecithin, pectin, alginate, ammonium alginate, sodium alginate, calcium, potassium, alginic acid propylene glycol, agar and natural gum for example arabic gum, karaya, locust bean, tragakanta, carrageenin, guar gum, flavochrome, scleroglucan and their mixture and admixture.Those skilled in the art will appreciate that and in coating, to add excipient for example plasticizer, lubricant, solvent or the like.Suitable plasticizer comprises for example acetyl monoglyceride; Butyl phthalyl butyl glycolate; Dibutyl tartrate; Diethyl phthalate; The phthalic acid dimethyl esters; Glycolic ethyl ethyl phthalate; Glycerol; Propylene glycol; Glyceryl triacetate; Citrate; Tripropioin; Diacetine; Dibutyl phthalate; Acetoglyceride one ester; Polyethylene Glycol; Oleum Ricini; Triethyl citrate; Polyhydric alcohol, glycerol, acetas, glyceryl triacetate, citric acid acetyl triethyl, dibenzyl phthalate, dihexylphthalate, butyl octyl phthalate, diisononyl phthalate, butyl octyl phthalate, dioctyl azelate, the tall oil acid epoxy-ester, triisooctyl trimellitate, the hexyl diethyl phthalate, dinoctyl phthalate, diisooctyl phthalate, diisooctyl phthalate, phthalic acid two n-undecane base esters, phthalic acid two n-tridecane esters, hexyl tri trimellitate-2-ethyl ester, hexyl adipic acid two-2-ethyl ester, hexyl decanedioic acid two-2-ethyl ester, hexyl Azelaic Acid two-2-ethyl ester, dibutyl sebacate.
Comprising when changing the release matrix material when change discharging component, can use the combination of any suitable change release matrix material or suitable change release matrix material.These materials are well known by persons skilled in the art.Term used herein " change release matrix material " comprises can change the hydrophilic polymer that is dispersed in external or intravital Ziprasidone or its salt or derivant and discharges, hydrophobic polymer and composition thereof.Be fit to implement change release matrix material of the present invention and include but not limited to, microcrystalline Cellulose, sodium carboxy methyl cellulose, hydroxy alkyl cellulose be for example methylcellulose and ethyl cellulose, Polyethylene Glycol, polyvinylpyrrolidone, cellulose acetate, cellulose acetate-butyrate, Cellacefate, Cellulose acetotrimellitate, phthalic acid polyvinylacetate, poly-alkylmethacrylate, polyvinyl acetate and composition thereof of hydroxypropyl emthylcellulose and hydroxypropyl cellulose, polyethylene glycol oxide, alkylcellulose for example.
Change release composition according to the present invention can be incorporated in any suitable dosage form, and wherein this dosage form promotes that active component discharges with pulse mode.In one embodiment, this dosage form comprises the particulate admixture that comprises active component of different piece, and it constitutes to discharge immediately and to change and discharges component, and this admixture is filled into suitable capsule, for example firmly or in the Perle.Alternately, the granule that comprises active component of different various pieces can be suppressed (choosing the excipient with other wantonly) and become tabloid, then it is filled in the capsule in the proper ratio.Another kind of suitable dosage form is a multilayer tablet.In this case, first component that changes release composition can be pressed into one deck, adds the second layer of second component as multilayer tablet subsequently.The granule that constitutes the each several part of compositions of the present invention may further include at rapid-dissolve dosage form, for example effervescent dosage form or melt in the dosage form fast.
In one embodiment, said composition comprises at least two kinds of components that comprise Ziprasidone: first component and one or more subsequent component.In this embodiment, first component of compositions can show different release profiles, comprise that the nearly all Ziprasidone that wherein comprises in first component discharges immediately behind form of administration, but after postponing a period of time, discharge (postponing to discharge) immediately, or slowly discharge in a period of time.In such embodiment, the Ziprasidone that comprises in first component after being applied to the patient discharges rapidly." discharging rapidly " used herein comprises such release profiles, wherein the active component at least about 80% is being used back release in about 1 hour in the component, term " postpones release " and comprises such release profiles, wherein the active component of component discharges (quick or slow) after postponing a period of time, term " sustained release " and " prolong and discharge " comprise such release profiles, and wherein contained active component slowly discharges at least about 80% in the component.
Second component of these embodiments also shows a lot of release profiles, comprises release profiles, delay release profiles and sustained release curve immediately.In such embodiment, the second component display delay release profiles, wherein Ziprasidone discharges after postponing a period of time.
Immediate-release component and at least a change that comprises the nanoparticle that contains Ziprasidone or contain Ziprasidone that dosage form of the present invention comprises the nanoparticle that contains Ziprasidone or comprise Ziprasidone discharge component, use curve of blood plasma that this dosage form produces and be substantially similar to twice of continuous administration or the curve of blood plasma that produces of I R dosage form repeatedly, or be similar to and use IR respectively and change the curve of blood plasma that release dosage form produces.Therefore, dosage form of the present invention for use need keep pharmacokinetic parameter but be that problematic Ziprasidone is useful especially.
In one embodiment, said composition discharges Ziprasidone with the solid oral dosage form that comprises said composition, so that the whole basically Ziprasidones that are included in before Ziprasidone discharges from least a subsequent component in first component all discharge.When first component comprises the IR component, after for example preferred hangover of Ziprasidone from least a subsequent component to the whole Ziprasidones in the IR component have basically all discharged.Such as detailed description, can postpone the release of Ziprasidone from least a subsequent component by use to change discharging coating and/or changing the release matrix material.
When needs make the patient to the dosage regimen toleration of the first dosage drug withdrawal of the promotion patient whole body Ziprasidone that provided hour, the hangover of Ziprasidone from subsequent component, whole basically Ziprasidones in first component all discharge, and further postpone, until from patient's whole body, removing to the small part Ziprasidone of from first component, discharging.In one embodiment, even the release of Ziprasidone from the subsequent component of compositions is not completely, also be to be delayed to basically to use after the said composition at least about 2 hours.In another embodiment, even the release of Ziprasidone from the subsequent component of compositions is not completely, also be to be delayed to basically to use after the said composition at least about 4 hours.
As described below, the present invention also comprises various types of change delivery systems, and Ziprasidone can discharge with pulse or continuation mode by this system.These systems include but not limited to: containing Ziprasidone or comprising the film (monolithic devices) of the nanoparticle of Ziprasidone in polymeric matrix; Ziprasidone or the nanoparticle that comprises Ziprasidone are included in the system's (storage medicine device) in the polymer; The polymerization micelle or the microcapsule (microgranule, microsphere or nanoparticle) of storage medicine and matrix device form; But Ziprasidone or the nanoparticle that comprises Ziprasidone are included in and contain for example system in the polymer of second polymer, surfactant or plasticizer etc. of hydrophilic and/or filtration additives, can be by the device (storing medicine and matrix device) of infiltration " control " to obtain Multiple-Aperture Device or its Chinese medicine; Enteric coating (ionizing is also suitably being dissolved under the pH); With Ziprasidone molecule (covalency) bonded (soluble) polymer that dangles; Device with dynamic sustained release speed: osmotic pumps for example.
Delivery mechanism of the present invention will be controlled the rate of release of Ziprasidone.Although some mechanism discharge Ziprasidone with constant speed, other then are different, are for example to change Concentraton gradient or filtration causes the function of the time of porous additive or the like according to various factors.
Continuing to discharge the polymer that uses in the coating must be biocompatibility, is biodegradable in theory.The example of natural polymer for example
(FMC Corporation, Food ﹠amp; Pharmaceutical Products Division, Philadelphia, USA) (mechanical ball changes into the ethyl cellulose of sub-micron, water base, puppet-latex dispersion) and in for example poly-(acrylate, methacrylate) the copolymer scope of synthetic polymer
(
Pharma is known in the art Weiterstadt.).
The storage medicine device
A typical approach that change to discharge is to incapsulate or medicine (for example, as nuclear) is completely contained in (that is microcapsule or spraying ,/dish coating is examined) in polymeric film or the coating.
The various factors that can influence diffusion process can easily be applied to store medicine device (for example effect of additive, functional (with consequent infiltration-pH value of solution), the porosity of polymer, film casting condition or the like), must think better of when therefore, medicine device is store in the selective polymer development.The model of setting up the wherein transportation of Ziprasidone and be the releasing properties of the storage medicine device (with monolithic devices) by solution diffusion mechanism generally includes relevant boundary condition
Fick Two laws(labile state condition; The concentration dependent flux) solution.When this device comprised dissolved activating agent, because the concentration (activity) (i.e. the driving force of Shi Fanging) of reagent descends (being that one-level discharges) in this device, rate of release is exponential type in time to be increased.But if activating agent in saturated suspension the time, the driving force that discharges keeps constant no longer saturated until this device so.Alternately, the kinetics of rate of release can be that desorption is controlled, and is the subduplicate function of time.
Compare with the thin film that does not contain polymer, owing to can form the closure property (permeability) of the coating nuclear of osmotic pressure (it plays a role then tablet is infiltrated) in inside, the transportation character of coated tablet can strengthen.
After deliberation the effect of deionized water for the saliniferous tablet of bag of poly-by comprising (ethylene glycol) silicone elastomer bag quilt (PEG), also studied the effect of water for free film.Find that the release of salt from tablet is the immixture in the hole that diffuses through the water filling that forms of hydration and osmotic pumps by coating.The KCl transportation can be ignored by the film that only comprises 10%PEG, although similarly observing expansion widely in the free film, show that porous is necessary for the release of KCl, strides the hole diffusion then.Find discous coating salt sheet swelling in deionized water, owing to the generation of interior hydrostatic pressure changes over oblate spherical: the change of shape provides the method for measuring the power that is produced.As expected, penetration is along with the level of PEG content improves and reduces.Lower PEG level can make the water infiltration by hydrated polymer, and simultaneously, the hole that the coating dissolving produces when PEG content is higher level (20 to 40%) makes can alleviate the mobile pressure of KCl.
Developed method and equation, can be used for calculating because salt discharges the osmotic pumps that produces and strides the dispersive relative value in hole from tablet by the release of monitoring (independently) two kinds of different salt (for example KCl and NaCl).When lower PEG level, owing to only produce lower hole count density, osmotic flow is much larger than striding the film diffusion: when load 20%, two kinds of mechanism are to equate generally for the effect that discharges.But the generation of hydrostatic pressure has reduced infiltration and has flowed into and osmotic pumps.When the PEG load was higher, the hole that contains moisture film was more, and is less to the effusive resistance of salt.Therefore, although osmotic pumps strengthens (with low load time compare), stride the film diffusion and remain main releasing mechanism.Reported that also the infiltration releasing mechanism can be used to comprise the microcapsule of water-soluble core.
Monolithic devices (matrix device)
Skeleton (substrate) device can be used to control the release of medicine.This may be that they are easy to make relatively owing to compare with the storage medicine device, does not also have the danger of the unexpected high dose that the film rupture of storing medicine device causes.In this device, activating agent exists with dispersion in polymeric matrix, and they form by compacting polymer mixture or by dissolving or fusing typically.The administration releasing properties of monolithic devices depends on the dissolubility of medicine in polymeric matrix, perhaps in the situation of porous matrix, the dissolubility of the percolating solution in particulate pore network and the curvature of this network (being greatly increased than permeability of the membrane) depend on whether medicine is dispersed in the polymer or is dissolved in the polymer.For the low load (0 to 5%W/V) of medicine, medicine discharges by solution dispersal mechanism (not having the hole).When higher load (5 to 10%W/V), because drug loss, the existence by near form the apparatus surface hole makes the releasing mechanism complexity: thus release rate of drugs has been improved with the liquid filling in the environment in these holes.
Usually, to matrix device (with the storage medicine device) add plasticizer (for example poly-(ethylene glycol)), surfactant or adjuvant (promptly increasing the composition of effectiveness) as strengthen infiltrative method (although, on the contrary, plasticizer can be temporary transient, just help film to form, therefore, reduced permeability-a kind of character that in polymer-coated coating, more needs usually).The effect that should be noted in the discussion above that leaching PEG makes that (ethyl cellulose) permeability of the membrane strengthens linearly, and by increasing hole, it is the function of PEG load, and still, this film has kept their shield property, does not allow the electrolyte transmission.Can inference, infiltrative enhancing is the result that thickness that the PEG leaching causes effectively reduces.When the PEG of load 50%W/W, what this showed as per unit area accumulates the chart of osmotic flow as the function of the inverse of time and film thickness: (Fick) solution diffusion type transport mechanism in homogeneous membrane as expected, this chart understand that between the inverse of infiltration rate and film thickness be linear relationship.The linear zone of this figure has obtained positive intercept to the extended line of time shaft on time shaft: along with reducing of film thickness, its size is reduced to 0.Help the time delay of these changes two kinds of diffusion flows (Ziprasidone stream and PEG stream) to take place, also help time delay more generally during the penetrating agent concentration in the establishment film at the commitment of experiment.When using caffeine, shown minus time delay as penetrating agent.Also can't make explanations to this, but it should be noted that caffeine has shown lower partition coefficient in this system, this also is the feature of aniline infiltration by polyethylene film, and it has shown similarly negative time delay.
After deliberation the effect of the surfactant that added for (hydrophobic) matrix device.It is believed that surfactant increases drug release rate by three kinds of possible mechanism: (i) solubilising, (ii) improve to " wettability " of dissolve medium with (iii) because the leaching surfactant has formed the hole.(plastifying for the system of being studied by Sorbitol
100 and RS 100, flurbiprofen is as medicine, the surfactant of certain limit), the moistening that can infer tablet improves and causes drug release that improve (it is diffusion that hint discharges, rather than controllably dissolving) of part only arranged, although this effect is
Greater than
Be those surfactants to discharging maximum influence simultaneously, they are easier to dissolving owing to producing to break in substrate, and this makes dissolve medium be easy near in the substrate.Since opposite when not containing surfactant, can easily prepare polymer emulsion with surfactant, obviously be relevant therefore with the research of the latex film that is suitable as drug coating.Found the difference-have only between these two kinds of polymer
Show the mutual relation between anion/cationic surfactant and the medicine.This is the level difference owing to quaternary ammonium ion on polymer.
Also there is the substrate composed set composite of polymer that is coated in the polymer that does not comprise medicine.This device is by aqueous
Emulsion constitutes, and finds that medicine can produce release continuously by shell diffusion from examine.Similarly, also made the polymer core that comprises medicine, but examined by this with the erodible shell bag of gastric juice.Find that release rate of drugs is linear relatively (function of the speed by shell restriction diffusion process), inversely proportional with the thickness of shell, on the contrary only find that the release meeting was slowed down along with the time from nuclear.
Microsphere
The method for preparing tiny balloon has been described.The ethanol/dichloromethane solution that comprises medicine and polymer by preparation prepares tiny balloon.After in pouring water into, formed the particulate emulsifying agent that comprises dispersive polymer/solvent by cohesion type process, ethanol obtains sealing the duricrust granule of the medicine that is dissolved in the dichloromethane at the surperficial rapid diffusion precipitation polymers of microdroplet thus.In granule, produced the gas phase of dichloromethane then, by after the shell diffusion, observed to the surface of the water bubble of emerging.Under reduced pressure hollow ball has been filled water, can remove by the drying of a period of time and anhydrate.In water, do not find medicine.High porosity matrix type microsphere has also been described.By medicine and polymer dissolution are prepared the matrix type microsphere in ethanol.Except water, ethanol disperses from the Emulsion microdroplet, the granule of remaining high porosity.The purposes of a suggestion of described microsphere is the floating drug delivery apparatus that uses under one's belt.
Device dangles
Developed and a kind of ester chain of poly-(acrylic acid) ester latex particle by aqueous emulsion polymerization preparation to a certain extent and adhere to for example method of analgesic and antidepressants or the like of medicine.When by ion exchange resin so that polymer end groups is when being transformed into their strong acid form, these latexes can self-catalysis ground hydrolysis by the ester chain discharge medicine.
Medicine is attached on the polymer, also with the medicine synthon that dangles that adheres to.Prepared dosage form; its Chinese medicine is incorporated into by unsettled chemical bonded refractory on the polymer of biocompatibility, for example by the polyanhydride of the acid anhydride preparation that replaces (by the prepared in reaction itself of acid chloride and medicine: the sodium salt of methacrylic chloride and methoxybenzoic acid) can be used for and second polymer
Form substrate, wherein the hydrolysis in gastric juice of second polymer discharges medicine.The purposes of the polymerization Schiff alkali of the carrier that is suitable as medicine amine has also been described.
Enteric film
Enteric coating comprises the pH sensitive polymer.Usually, polymer is carboxylated, and under low pH and the effect between the water very little, under high pH, polymer ionsization causes the swelling or the dissolving of polymer simultaneously.Therefore, coating can be designed in the sour environment of stomach be kept perfectly (the protection Ziprasidone is avoided this environment or protected stomach to avoid the destruction of this medicine), but can dissolve in the more alkaline environment of intestinal.
The infiltration control device
Osmotic pumps is similar to the storage medicine device, but comprises the penetrating agent (for example activating agent of salt form) that water is penetrated into surrounding medium by semipermeable membrane.The device of " basic osmotic pumps " has also been described this being called.In device, produced pressure, this device comes out activating agent by the aperture from device, the size design in aperture makes the solution diffusion minimum, has prevented the growth of hydrostatic pressure head simultaneously, and this hydrostatic pressure head has the effect of the big small size that reduces osmotic pressure and modifier.Simultaneously, it is constant that the inner volume of device keeps, and excessive solid or saturated solution are arranged in device, and rate of release keeps constant so, and the volume of sending equals the volume of the solvent that absorbed.
The releasing device of electricity irritation
Go out monolithic devices with the polyelectrolyte preparing gel, described gel swelling when for example using external electric to stimulate causes pH to change.Can come adjustment release by changing applied electric current, obtain constant or the pulsed release profiles.
Hydrogel
Except they are used for the drug matrices, find that hydrogel can be used for a lot of biochemical purposes, for example soft contact lens and various soft implants or the like.
III. use the method for the change release composition that comprises Ziprasidone
According to another aspect of the present invention, provide a kind of method for the treatment of the patient who suffers from schizophrenia or relevant psychiatric disturbance, comprise the step of compositions of the present invention of the solid oral dosage form form of administering therapeutic effective dose.The advantage of method of the present invention comprises and reduces the conventional repeatedly administration frequency of IR dosage regimen needs, and the while has still kept benefit or elimination that the pulsed curve of blood plasma obtains or the variation minimum that makes the plasma concentration level.The minimizing administration frequency is useful for patient's compliance, and the method for the application of the invention reduces administration frequency and may help to control the health care expense by the time that minimizing hygiene care personnel are spent after using Ziprasidone.
In following embodiment, all except as otherwise noted percentage ratio is percentage by weight.The term that uses in whole embodiment " pure water " is meant its water by the water filtering system purification.Should be understood that embodiment is only used for purpose of explanation, and should not be interpreted as the spirit and scope of the present invention are limited that described spirit and scope are as the scope definition of hereinafter claim.
Embodiment
Embodiment 1 to 4 provides exemplary Ziprasidone tablet.These embodiment are intended to where face restriction claim in office, and provide the exemplary Ziprasidone tablet that can be used for method of the present invention.These exemplary tablets also can comprise coating materials.
Embodiment 1
Embodiment 2
Embodiment 3
Embodiment 4
Embodiment 5
The many granules that comprise Ziprasidone change release composition
Be prepared as follows many granules according to the present invention and change release composition, it comprises the immediate-release component that contains Ziprasidone and changes the release component.
(a) discharge (IR) component immediately.
The solution of any formulation preparation Ziprasidone that provides according to table 1.For example use then Glatt GPCG3 (Glatt, Protech Ltd., Leicester, UK) the fluidized bed coating device by to good seed, reaches about 16.9% solid weightening finish level with methylphenidate solution bag, has formed the IR granule of immediate-release component.
Table 1
Immediate-release component solution
Amount, % (w/w)
Composition (i) (ii)
Ziprasidone 13.0 13.0
Polyethylene glycol 6000 0.5 0.5
Polyvinylpyrrolidone 3.5
Pure water 83.5 86.5
(b) change the release component
Preparation comprises the delayed release granule of Ziprasidone, discharges coating solution bag by the release particles immediately according to the foregoing description 5 (a) preparation by being used in the change of describing in detail in the table 2.With fluidized bed plant for example with the varying level bag by this release particles immediately, be up to about 30% weightening finish.
Table 2
Change and discharge component coating solution
Amount, % (w/w)
Composition (i) (ii) (iii) (iv) (v) (vi) (vii) (viii)
RS?12.5
-- -- -- -- -- 54.35 46.5
S?12.5
L?12.5
Polyethylene pyrroles------0.35 0.3------
Alkane ketone
Phthalic acid 0.5 0.5 0.6 1.35 0.6 1.3 1.1--
Diethylester
Triethyl citrate--------------1.25
Isopropyl alcohol 39.8 33.1 37.2 45.1 33.8 44.35 49.6 46.5
Acetone 10.0 8.3 9.3--8.4------
Talcum
1--16.0 5.9--16.3--2.8 2.25
1At row (i), (iv) and (in the preparation vi), Talcum is to use in coating.
(c) discharge immediately and the capsule of delayed release granule
Use for example Bosch GKF 4000S encapsulation device, with No. 2 hard gelatin capsules will be according to embodiment 5 (a) and (b) preparation become 20mg dose intensity altogether with the delayed release granule encapsulation immediately.The accumulated dose intensity of 20mg Ziprasidone is included in the 10mg in the immediate-release component and is changing the 10mg that discharges in the component.
Embodiment 6
The many granules that comprise Ziprasidone change release composition
According to table 3 (a) and the formulation preparation (b) change the Ziprasidone compositions that discharges according to many granules according to the present invention, its change that has immediate-release component and contain the release matrix material that changes discharges component.
Table 3 (a)
Change with 100mg discharges the IR component encapsulation of (MR) component with 100mg, obtains the product % (w/w) of 20mg dose intensity
The IR component
Ziprasidone 10
Microcrystalline Cellulose 40
Lactose 45
Polyvidone 5
The MR component
Ziprasidone 10
Microcrystalline Cellulose 40
Polyvidone 5
Table 3 (b)
Change with 50mg discharges the IR component encapsulation of (MR) component with 50mg, obtains the product % (w/w) of 20mg dose intensity
The IR component
Ziprasidone 20
Microcrystalline Cellulose 50
Lactose 28
Polyvidone 2
The MR component
Ziprasidone 20
Microcrystalline Cellulose 50
Polyvidone 2
Embodiment 7
The purpose of present embodiment is to describe the Ziprasidone compositions that how to prepare nanoparticle.
For example hydroxypropyl cellulose (HPC-SL) and dioctylsulfosuccinat are combined in the aqueous dispersions of 5% (w/w) Ziprasidone and one or more surface stabilizers
0.01 (NanoMill Systems, King of Prussia, PA; Referring to for example, U.S.6,431,478) the 10ml chamber in grind, wherein this lapping device has 500 microns
Abrasive media (Dow Chemical) (for example, the medium of load 89%).In an exemplary process, this mixture was ground 60 minutes under the grinding rate of 2500rpm.
In the Ziprasidone particle grain size that can in deionized water, measure with Horiba LA-910 granularmetric analysis device after the grinding after grinding.For the compositions of success, expect that initial meansigma methods and/or D50 grind the particle diameter of back Ziprasidone less than 2000nm.
Those skilled in the art can make various changes and change, and not break away from the spirit and scope of the present invention apparently in method and composition of the present invention.Therefore, the present invention covers change of the present invention and change, as long as they are in the scope and their equivalent scope of appended claims.
Claims (91)
1. stable nanoparticle compositions, comprise: (A) comprise the granule of Ziprasidone, described particulate effective mean diameter is that diameter is less than about 2000nm; (B) at least a surface stabilizer.
2. the compositions of claim 1, wherein said granule is selected from crystal phase, amorphous phase, hemihedral crystal bulk phase, half amorphous phase and composition thereof.
3. the compositions of claim 1, wherein said particulate effective mean diameter is to be selected from diameter less than about 1900nm, less than about 1800nm, less than about 1700nm, less than about 1600nm, less than about 1500nm, less than about 1400nm, less than about 1300nm, less than about 1200nm, less than about 1100nm, less than about 1000nm, less than about 900nm, less than about 800nm, less than about 700nm, less than about 600nm, less than about 500nm, less than about 400nm, less than about 300nm, less than about 250nm, less than about 200nm, less than about 100nm, less than about 75nm and the group formed less than about 50nm.
4. the compositions of claim 1, wherein said composition is mixed with
(A) be used for by be selected from parenteral, oral, vagina, nose, rectum, ear, eye, part, containing, the brain pond, intraperitoneal or local application;
(B) form a kind of dosage form, be selected from tablet, capsule, wafer, solution, dispersion, gel, aerosol, ointment, emulsifiable paste and its mixture;
(C) formed a kind of dosage form, be selected from the sustained release dosage form, fast melt dosage form, freeze-dried formulation, delayed release dosage forms, prolongation release dosage form, pulsed release dosage form, and discharge immediately and sustained release mixed type dosage form; Or
(D) (A), (B) or combination in any (C).
5. the compositions of claim 1 wherein further comprises the acceptable excipient of one or more pharmacy, carrier or its combination.
6. the compositions of claim 1, wherein:
(A) based on total mixing dry weight of Ziprasidone in the compositions and surface stabilizer, and do not comprise other excipient, the amount of described Ziprasidone in described compositions is from about 99.5% to about 0.001%, about 95% to about 0.1% or about 90% to about 0.5 weight %;
(B) based on total mixing dry weight of Ziprasidone in the compositions and surface stabilizer, and do not comprise other excipient, the amount of described one or more surface stabilizers in described compositions is from about 0.5% to about 99.999%, about 5.0% to about 99.9% or about 10% to about 99.5 weight %; Or
(C) combination (A) and (B).
7. the compositions of claim 1, wherein surface stabilizer is selected from the group that nonionic surface stabilizer, anionic surface stabilizing agent, cationic surface stabilizing agent, amphion surface stabilizer and ion-type surface stabilizer are formed.
8. the compositions of claim 1, wherein surface stabilizer is selected from cetylpyridinium chloride, gelatin, casein, phospholipid, glucosan, glycerol, arabic gum, cholesterol, the tragakanta, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, the octadecanol hexadecanol, cetomacrogol emulsifying wax, the sorbitan ester, polyoxyethylene alkyl ether, castor oil derivatives, polyoxyethylene Sorbitan acid anhydride fatty acid ester, Polyethylene Glycol, Dodecyl trimethyl ammonium chloride, Myrj 45, silica sol, phosphate ester, sodium laurylsulfate, carboxymethylcellulose calcium, hydroxypropyl cellulose, hypromellose, sodium carboxymethyl cellulose, methylcellulose, hydroxyethyl-cellulose, hydroxypropyl first O-phthalic acid cellulose, non-microcrystalline Cellulose, aluminium-magnesium silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, 4-(1,1,3,3-tetramethyl butyl)-polymer of phenol and oxirane and formaldehyde, poloxamer; The mixture of dialkyl, sodium laurylsulfate, alkyl aryl polyether sulfonate, sucrose stearate and the sucrose distearate of poloxamines, charged phospholipid, dioctyl sulfosuccinate, sodium sulfosuccinate, right-different Nonylphenoxy gather-((+)-2,3-Epoxy-1-propanol), capryl-N-methyl glucoside amine; Positive decyl β-D-pyranglucoside; Positive decyl β-D-pyrans maltoside; Positive lauryl β-D-pyranglucoside; Positive lauryl β-D-maltoside; Heptanoyl group-N-methyl glucoside amide; N-heptyl-β-D-pyranglucoside; N-heptyl β-D-thioglycoside; N-hexyl β-D-pyranglucoside; Pelargonyl group-N-methyl glucoside amide; Pelargonyl group β-D-pyranglucoside; Caprylyl-N-methyl glucoside amine; N-octyl-β-D-pyranglucoside; Octyl group β-D-pyrans thioglycoside; Lysozyme, PEG-phospholipid, the PEG-cholesterol, the PEG-cholesterol derivative, the PEG-vitamin A, the PEG-vitamin E, lysozyme, the randomcopolymer of vinyl acetate and vinylpyrrolidone, cationic polymer, cationic biopolymers, cationic polysaccharide, the cationic cellulose class, the cation alginate, cation non-polymerization chemical compound, cationic phospholipid, cation lipid, poly-methyl acrylic acid trimethylammonium bromide, sulfonium compound, polyvinylpyrrolidone-2-dimethyl aminoethyl dimethylaminoethyl acrylate methyl sulfuric ester, cetyl trimethyl ammonium bromide phosphonium compounds, quaternary ammonium compound, benzyl-two (2-chloroethyl) ethyl ammonium bromide, the Cortex cocois radicis trimethyl ammonium chloride, the Cortex cocois radicis trimethylammonium bromide, Cortex cocois radicis methyl dihydroxy ethyl ammonium chloride, Cortex cocois radicis methyl dihydroxy ethyl ammonium bromide, the decyl triethyl ammonium chloride, decyl dimethyl hydroxyl ethyl ammonium chloride, decyl dimethyl hydroxyl bromic ether ammonium chloride, C
12-15Dimethyl hydroxyl ethyl ammonium chloride, C
12-15Dimethyl hydroxyl bromic ether ammonium chloride, Cortex cocois radicis dimethyl hydroxyl ethyl ammonium chloride, Cortex cocois radicis dimethyl hydroxyl ethyl ammonium bromide, myristyl trimethyl ammonium methylsulfuric acid ester, lauryl dimethyl benzyl ammonium chloride, lauryl dimethyl benzyl ammonium bromide, lauryl dimethyl (ethyleneoxy)
4Ammonium chloride, lauryl dimethyl (ethyleneoxy)
4Ammonium bromide, N-alkyl (C
12-18) dimethyl benzyl ammonium chloride, N-alkyl (C
14-18) dimethyl-benzyl ammonium chloride, N-myristyl dimethyl benzyl ammonium chloride monohydrate, dimethyl didecyl ammonium chloride, N-alkyl and (C
12-14) dimethyl 1-naphthyl methyl ammonium chloride, trimethyl-ammonium halide, alkyl-leptodactyline, dialkyl group-dimethyl ammonium, lauryl trimethyl ammonium chloride, ethoxylated alkyl amidoalkyl dialkyl ammonium salt, ethoxylation trialkyl ammonium salts, dialkyl benzene dialkylammonium chloride, N-DDAC, N-myristyl dimethyl benzyl ammonium chloride monohydrate, N-alkyl (C
12-14) dimethyl 1-naphthyl methyl ammonium chloride, lauryl dimethyl benzyl ammonium chloride, dialkyl benzene alkyl ammomium chloride, lauryl trimethyl ammonium chloride, alkyl benzyl ammonio methacrylate, alkyl benzyl dimethyl ammonium bromide, C
12Trimethylammonium bromide, C
15Trimethylammonium bromide, C
17Trimethylammonium bromide, lauryl benzyltriethylammoinium chloride, poly--diallyldimethylammonium chloride (DADMAC), alkyl dimethyl ammonium chloride, alkyl dimethyl ammonium halide, three cetyl ammonio methacrylates, decyl trimethylammonium bromide, lauryl triethyl group ammonium bromide, Tetradecyl Trimethyl Ammonium Bromide, methyl trioctylphosphine ammonium chloride, POLYQUAT10
TM, tetrabutyl ammonium bromide, halogeno salt, the MIRAPOL of benzyltrimethylammonium bromide, cholinester, benzalkonium chloride, stearyl dimethyl benzyl ammonium chloride, brocide, cetylpyridinium chloride, oxozone ethyl alkylamine
TM, ALKAQUA T
TM, Fixanol; Amine, amine salt, amine oxide, acid imide azolinium salt, protonated season acrylamide, methylated tetravalence polymer and cation guar gum.
9. the compositions of claim 1 is wherein compared with fasted conditions, and said composition can not produce significantly different absorption level when using under the condition on the feed.
10. the compositions of claim 1, the patient who wherein compositions is applied to fasting state is bioequivalent with the patient who is applied to the feed state.
11. the compositions of claim 1, wherein the pharmacokinetic curve of said composition can not be subjected to absorbing patient's the feed of described compositions or the appreciable impact of fasting state.
12. the compositions of claim 1, wherein give the described compositions of administration after, compositions has produced therapeutic effect under the dosage less than the non-nanoparticle dosage form of identical Ziprasidone.
13. the compositions of claim 1, it has:
(a) when using the blood plasma of post analysis mammalian subject, the C of Ziprasidone
MaxC greater than the non-nanoparticle preparation of the identical Ziprasidone of using same dose
Max
(b) when using the blood plasma of post analysis mammalian subject, the AUC of Ziprasidone is greater than the AUC of the non-nanoparticle preparation of the identical Ziprasidone of using same dose;
(c) when using the blood plasma of post analysis mammalian subject, the T of Ziprasidone
MaxT less than the non-nanoparticle preparation of the identical Ziprasidone of using same dose
MaxOr
(d) (a) and (b) and combination in any (c).
14. the compositions of claim 1 also comprises the reactive compound that one or more are used to prevent and treat schizophrenia and similar psychiatric disturbance.
15. the compositions of claim 14, wherein one or more chemical compounds are selected from the group of the chemical compound composition of the disease that is used for the treatment of the group that is selected from headache, misery, heating and its combination composition.
16. the compositions of claim 1, wherein said granule comprises the medicine storage device that contains Ziprasidone, and described medicine storage device seals the semipermeable membrane that water is drawn in the granule by permission, has therefore produced the pressure that described Ziprasidone is disengaged from described granule.
17. the compositions of claim 1, wherein said medicine storage device also comprises penetrating agent.
18. method for compositions for preparing claim 1, being included in is enough to provide that to have effective mean diameter be that the granule that will comprise described Ziprasidone contacts a period of time with at least a surface stabilizer under the condition of diameter less than the nanoparticle compositions that comprises Ziprasidone of about 2000nm.
19. the method for claim 18, wherein this contact comprises grinding, wet grinding, homogenize, precipitation, plate emulsifying or supercritical liq granule generating technique.
20. the method for claim 18, wherein the particulate effective mean diameter of this nanoparticle is to be selected from diameter less than about 1900nm, less than about 1800nm, less than about 1700nm, less than about 1600nm, less than about 1500nm, less than about 1400nm, less than about 1300nm, less than about 1200nm, less than about 1100nm, less than about 1000nm, less than about 900nm, less than about 800nm, less than about 700nm, less than about 600nm, less than about 500nm, less than about 400nm, less than about 300nm, less than about 250nm, less than about 200nm, less than about 100nm, less than about 75nm with less than about 50nm.
21. a method that prevents and/or treats schizophrenia or similar psychiatric disturbance comprises the compositions of using according to claim 1.
22. the method for claim 21, wherein the particulate effective mean diameter of this nanoparticle is to be selected from diameter less than about 1900nm, less than about 1800nm, less than about 1700nm, less than about 1600nm, less than about 1500nm, less than about 1000nm, less than about 1400nm, less than about 1300nm, less than about 1200nm, less than about 1100nm, less than about 900nm, less than about 800nm, less than about 700nm, less than about 600nm, less than about 500nm, less than about 400nm, less than about 300nm, less than about 250nm, less than about 200nm, less than about 100nm, less than about 75nm with less than about 50nm.
23. pharmaceutical composition, comprise the granule that comprises active component of first component and the granule that comprises active component of at least one subsequent component, wherein at least a described component comprises Ziprasidone, at least a described component further comprises and change to discharge coating, changes the release matrix material or both have concurrently, so that after giving patient's oral delivery, said composition is with bimodal or multimodal mode delivering active ingredients.
24. the compositions of claim 23, wherein every kind of component all comprises the granule that contains Ziprasidone.
25. the compositions of claim 23, wherein said composition comprises the granule that comprises Ziprasidone of first component and the granule that comprises Ziprasidone of a subsequent component.
26. the compositions of claim 25, wherein first component comprises immediate-release component, and second component comprises change and discharges component.
27. the compositions of claim 23, wherein this granule that comprises active component is an erodable.
28. further comprising to change, the compositions of claim 23, wherein at least a described component discharge coating.
29. further comprising, the compositions of claim 23, wherein at least a described component change the release matrix material.
30. the compositions of claim 29, wherein said change release matrix material are selected from the group that hydrophilic polymer, hydrophobic polymer, natural polymer, synthetic polymer and composition thereof are formed.
31. the compositions of claim 30, wherein said Ziprasidone is discharged in the surrounding by corrosion.
32. the compositions of claim 31, wherein said compositions further comprises reinforcing agent.
33. the compositions of claim 30 comprises the Ziprasidone of about 0.1mg to about 1g.
34. pharmaceutical composition, comprise the granule that comprises active component of first component and the granule that comprises active component of at least one subsequent component, wherein at least a described component comprises Ziprasidone, at least a described component further comprises and change to discharge coating, changes the release matrix material or both have concurrently, so that after giving patient's oral delivery, said composition is delivering active ingredients in a continuous manner.
35. the compositions of claim 34, wherein every kind of component all comprises the granule that contains Ziprasidone.
36. the compositions of claim 34, wherein said composition comprises the granule that comprises Ziprasidone of first component and the granule that comprises Ziprasidone of a subsequent component.
37. the compositions of claim 36, wherein first component comprises immediate-release component, and second component comprises change and discharges component.
38. the compositions of claim 34, wherein this granule that comprises active component is an erodable.
39. further comprising to change, the compositions of claim 34, wherein at least a described component discharge coating.
40. further comprising, the compositions of claim 34, wherein at least a described component change the release matrix material.
41. the compositions of claim 40, wherein said change release matrix material are selected from the group that hydrophilic polymer, hydrophobic polymer, natural polymer, synthetic polymer and composition thereof are formed.
42. the compositions of claim 41, wherein said Ziprasidone is discharged in the surrounding by corrosion.
43. the compositions of claim 42, wherein said compositions further comprises reinforcing agent.
44. the compositions of claim 41 comprises the Ziprasidone of about 0.1mg to about 1g.
45. a dosage form comprises the compositions of claim 23.
46. the dosage form of claim 45 comprises the particulate admixture that contains active component that is included in hard gelatin capsule or the Perle.
47. the dosage form of claim 46, the granule that wherein contains active component is the form of tabloid, and this capsule comprises the mixture of described tabloid.
48. the dosage form of the claim 47 of tablet form.
49. the dosage form of claim 48, the wherein said granule that contains Ziprasidone is a rapid-dissolve dosage form.
50. the dosage form of claim 48, wherein this tablet is to melt tablet fast.
51. a dosage form comprises the compositions of claim 34.
52. the dosage form of claim 51 comprises the particulate admixture that contains active component that is included in hard gelatin capsule or the Perle.
53. the dosage form of claim 52, the granule that wherein contains active component is the form of tabloid, and this capsule comprises the mixture of described tabloid.
54. the dosage form of the claim 53 of tablet form.
55. the dosage form of claim 54, the granule that wherein comprises Ziprasidone is a rapid-dissolve dosage form.
56. the dosage form of claim 54, wherein this tablet is to melt tablet fast.
57. one kind prevents and/or treats the schizophrenia or the similar method of psychiatric disturbance, comprises the step of compositions of the claim 23 of administering therapeutic effective dose.
58. one kind prevents and/or treats the schizophrenia or the similar method of psychiatric disturbance, comprises the step of compositions of the claim 34 of administering therapeutic effective dose.
59. the compositions of claim 28, wherein said change discharge coating and comprise pH-dependent polymers coating, are used for after described compositions is applied to described patient, discharge the pulse of active component after 6 to 12 hours in described patient in time delay.
60. the compositions of claim 59, wherein said polymer coating comprises methacrylate copolymer.
61. the compositions of claim 59, wherein said polymer coating comprise the mixture of methacrylate and quaternary amine ylmethyl acrylate copolymer, its ratio is enough to realize the pulse of active component after postponing at least about 6 hours time.
62. the compositions of claim 61, wherein the ratio of methacrylate and quaternary amine ylmethyl acrylate copolymer is about 1: 1.
63. the compositions of claim 39, wherein said change discharge coating and comprise pH-dependent polymers coating, are used for after described compositions is applied to described patient, discharge the pulse of active component after 6 to 12 hours in described patient in time delay.
64. the compositions of claim 63, wherein said polymer coating comprises methacrylate copolymer.
65. the compositions of claim 64, wherein said polymer coating comprise the mixture of methacrylate and quaternary amine ylmethyl acrylate copolymer, its ratio is enough to realize the pulse of active component after postponing at least about 6 hours time.
66. the compositions of claim 65, wherein the ratio of methacrylate and quaternary amine ylmethyl acrylate copolymer is about 1: 1.
67. a sustained release compositions comprises nanoparticle granule partly, it comprises: (A) Ziprasidone; (B) change to discharge coating or, alternatively or additionally, change the stroma ground substance that discharges; So that said composition is sent Ziprasidone with pulse or continuation mode after giving patient's oral delivery.
68. the compositions of claim 67 is wherein compared with fasted conditions, described compositions can not produce significantly different absorption level when using under the condition on the feed.
69. the compositions of claim 67, the pharmacokinetic curve of wherein said compositions can not be subjected to absorbing patient's the feed of described compositions or the appreciable impact of fasting state.
70. the compositions of claim 67, the patient who wherein described compositions is applied to fasting state is bioequivalent with the patient who is applied to the feed state.
71. the compositions of claim 67, wherein this part comprises the change release particles.
72. the compositions of claim 67, wherein this part is the preparation of erodable.
73. the compositions of claim 67, wherein said granule all are the forms of permeability apparatus.
74. the compositions of claim 71, wherein this change release particles comprises change release coating.
75. the compositions of claim 71, wherein this change release particles comprises change release matrix material.
76. the compositions of claim 71, wherein said change release particles are combined to by corrosion described Ziprasidone are discharged in the preparation in the surrounding.
77. the compositions of claim 71 further comprises reinforcing agent.
78. the compositions of claim 71, the amount of the active component that wherein comprises are that about 0.1mg is to about 1g.
79. a dosage form comprises the compositions of claim 67.
80. the dosage form of claim 79 comprises the particulate admixture that contains active component that is included in hard gelatin capsule or the Perle.
81. the dosage form of claim 80, the granule that wherein contains active component is the form of tabloid, and this capsule comprises the mixture of described tabloid.
82. the dosage form of the claim 81 of tablet form.
83. the dosage form of claim 82, the granule that wherein comprises Ziprasidone is a rapid-dissolve dosage form.
84. the dosage form of claim 82, wherein this tablet is to melt tablet fast.
85. one kind prevents and/or treats the schizophrenia or the similar method of psychiatric disturbance, comprises the compositions of the claim 67 of administering therapeutic effective dose.
86. the compositions of claim 71 wherein changes release particles and comprises pH-dependent polymers coating, it is discharging in the pulse release of active component after 6 to 12 hours in time delay be effective.
87. the compositions of claim 86, wherein this polymer coating comprises methacrylate copolymer.
88. the compositions of claim 86, wherein this polymer coating comprises the mixture of methacrylate and quaternary amine ylmethyl acrylate copolymer, and its ratio is enough to realize the pulse of active component after time delay.
89. the compositions of claim 88, wherein the ratio of methacrylate and quaternary amine ylmethyl acrylate copolymer is about 1: 1.
90. the compositions of claim 67, wherein said granule all are the forms of permeability apparatus.
91. the compositions of claim 1, wherein said composition is mixed with the bank dosage form.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69209605P | 2005-06-20 | 2005-06-20 | |
US60/692,096 | 2005-06-20 | ||
US11/372,857 US20060240105A1 (en) | 1998-11-02 | 2006-03-10 | Multiparticulate modified release composition |
US11/372,857 | 2006-03-10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800302325A Division CN101242813A (en) | 2005-06-20 | 2006-06-19 | Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101879140A true CN101879140A (en) | 2010-11-10 |
Family
ID=37809174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010102092071A Pending CN101879140A (en) | 2005-06-20 | 2006-06-19 | The nanoparticle and the sustained release compositions that comprise aryl-heterocyclic compounds |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1901722A4 (en) |
KR (1) | KR20080024206A (en) |
CN (1) | CN101879140A (en) |
AU (1) | AU2006285349A1 (en) |
BR (1) | BRPI0612297A2 (en) |
CA (1) | CA2613474A1 (en) |
EA (1) | EA200800092A1 (en) |
HK (1) | HK1117060A1 (en) |
IL (1) | IL188093A0 (en) |
NO (1) | NO20076628L (en) |
SG (1) | SG162811A1 (en) |
WO (1) | WO2007027273A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107530284A (en) * | 2015-02-23 | 2018-01-02 | 翁特拉制药公司 | Millimeter capsule preparation including how unsaturated free fatty |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0909818A2 (en) * | 2008-03-07 | 2015-10-06 | Pfizer | methods, dosage forms and kit for administering ziprasidone without food |
DE102008045854A1 (en) | 2008-09-05 | 2010-03-11 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Particles of ziprasidone and a disintegrant containing pharmaceutical composition |
WO2010082855A1 (en) * | 2009-01-15 | 2010-07-22 | Zaklady Farmaceutyczne Polpharma Sa | Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation |
US20130108701A1 (en) | 2010-05-25 | 2013-05-02 | Krishna Murthy Bhavanasi | Solid Dosage Forms of Antipsychotics |
SG10201808645TA (en) | 2013-12-16 | 2018-11-29 | Massachusetts Inst Technology | Fortified Micronutrient Salt Formulations |
WO2015095230A1 (en) * | 2013-12-16 | 2015-06-25 | Massachusetts Institute Of Technology | Micromolded or 3-d printed pulsatile release vaccine formulations |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
NZ248813A (en) * | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
US6150366A (en) * | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
CA2653839A1 (en) * | 1998-11-02 | 2000-05-11 | John G. Devane | Multiparticulate modified release composition |
CZ20014230A3 (en) * | 1999-05-27 | 2002-08-14 | Pfizer Products Inc. | Suspension of ziprasidone |
AU2003267788A1 (en) * | 2002-10-25 | 2004-05-13 | Pfizer Products Inc. | Novel injectable depot formulations |
TW200526221A (en) * | 2003-09-02 | 2005-08-16 | Imran Ahmed | Sustained release dosage forms of ziprasidone |
US20080193542A1 (en) * | 2005-04-13 | 2008-08-14 | Pfizer Inc. | Injectable Deopot Formulations and Methods For Providing Sustained Release of Nanoparticle Compositions |
-
2006
- 2006-06-19 EP EP06773467A patent/EP1901722A4/en not_active Withdrawn
- 2006-06-19 AU AU2006285349A patent/AU2006285349A1/en not_active Abandoned
- 2006-06-19 WO PCT/US2006/023695 patent/WO2007027273A1/en active Application Filing
- 2006-06-19 BR BRPI0612297-3A patent/BRPI0612297A2/en not_active IP Right Cessation
- 2006-06-19 KR KR1020087001338A patent/KR20080024206A/en not_active Application Discontinuation
- 2006-06-19 CN CN2010102092071A patent/CN101879140A/en active Pending
- 2006-06-19 EA EA200800092A patent/EA200800092A1/en unknown
- 2006-06-19 SG SG201004372-7A patent/SG162811A1/en unknown
- 2006-06-19 CA CA002613474A patent/CA2613474A1/en not_active Abandoned
-
2007
- 2007-12-12 IL IL188093A patent/IL188093A0/en unknown
- 2007-12-21 NO NO20076628A patent/NO20076628L/en not_active Application Discontinuation
-
2008
- 2008-09-16 HK HK08110215A patent/HK1117060A1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107530284A (en) * | 2015-02-23 | 2018-01-02 | 翁特拉制药公司 | Millimeter capsule preparation including how unsaturated free fatty |
Also Published As
Publication number | Publication date |
---|---|
KR20080024206A (en) | 2008-03-17 |
IL188093A0 (en) | 2008-03-20 |
EA200800092A1 (en) | 2008-06-30 |
EP1901722A4 (en) | 2011-06-15 |
EP1901722A1 (en) | 2008-03-26 |
HK1117060A1 (en) | 2009-01-09 |
AU2006285349A1 (en) | 2007-03-08 |
NO20076628L (en) | 2008-03-12 |
CA2613474A1 (en) | 2007-03-08 |
BRPI0612297A2 (en) | 2010-11-03 |
SG162811A1 (en) | 2010-07-29 |
WO2007027273A1 (en) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101171000A (en) | Nanoparticulate and controlled release compositions comprising cyclosporine | |
CN101287451A (en) | Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor | |
CN101484169A (en) | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone | |
CN101410098B (en) | Microspheres comprising nanocapsules containing a lipophilicdrug | |
US7923026B2 (en) | Embedded micellar nanoparticles | |
CN101484170A (en) | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone | |
CN101287453A (en) | Nanoparticulate and controlled release compositions comprising a cephalosporin | |
AU2007312233B2 (en) | Micellar nanoparticles of chemical substances | |
CN101259106A (en) | Nano controlled release compositions comprising a cephalosporin | |
US20080102121A1 (en) | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone | |
CN101237868A (en) | Nanoparticulate clopidogrel and aspirin combination formulations | |
BRPI0716436B1 (en) | controlled release system and method for manufacturing it | |
BRPI0513904B1 (en) | multiparticulate pharmaceutical form for low solubility active substances and a process for preparing the pharmaceutical form | |
CN101879140A (en) | The nanoparticle and the sustained release compositions that comprise aryl-heterocyclic compounds | |
JP2007507553A (en) | Pantoprazole multiparticulate formulation | |
US20200206139A1 (en) | Compositions for the improved delivery of drugs | |
JP2018531985A (en) | Extended release film coated capsule | |
US20150342893A1 (en) | Celecoxib formulations useful for treating colorectal cancer | |
BRPI0714173A2 (en) | stable nanoparticulate composition, methods for preparing the composition, for preventing and / or treating disease conditions, symptoms, syndromes and conditions of the central nervous system, for improving or maintaining bioavailability of modafinil, and for treating neurologically based disorder, pharmaceutical composition, and dosage form | |
CN102655856A (en) | Nanoparticulate olmesartan medoxomil compositions, process for the preparation thereof and pharmaceutical compositions containing them | |
CN101132768A (en) | Nanoparticulate tacrolimus formulations | |
CN101242813A (en) | Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds | |
JP2009517485A (en) | Nanoparticulate and controlled release compositions containing cefditoren | |
US20220395514A1 (en) | Low-dose celecoxib preparation | |
Noor et al. | PHARMACEUTICAL TECHNIQUES FOR THE FABRICATION OF POOR WATER SOLUBLE DRUGS-A REVIEW. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20101110 |